

# CURA TECHNOLOGIES LIMITED

CIN:L84120TG1991PLC013479

To,

Date: 05.09.2025

1. BSE Limited, P.J. Towers, Dalal Street, Mumbai-400001 Scrip Code: 532332	2. National Stock Exchange of India Limited, Exchange Plaza, Bandra- Kurla Complex, Mumbai-400051 Symbol: CURAA
--	--

Dear Sir/Madam,

Sub: Notice of Annual General Meeting and submission of 34<sup>th</sup> Annual Report for the Financial Year 2024-25 under Regulation 34 of SEBI (LODR) Regulation 2015

Unit: Cura Technologies Limited

With reference to the subject cited, this is to inform the Exchanges that the Annual General Meeting is scheduled to be held on Monday, 29.09.2025 at 3.00 p.m. through video conferencing/OAVM. Please find enclosed the 34<sup>th</sup> Annual Report of the Company for the Financial Year 2024-25.

The cut-off date for the same is, 22<sup>nd</sup> September 2025. The Book closure date for the same is from 23.09.2025 to 29.09.2025.

This is for the information and records of the Exchanges, please.

Thanking you.

Yours sincerely,  
For Cura Technologies Limited

Digitally signed by  
Sangareddyeta Sai  
Kiran  
Date: 2025.09.05  
17:28:25 +05'30'

S. Sai Kiran  
Whole Time Director & CFO  
DIN: 09741325

Encl: as above

Reg.Off: Unit No 604 B, Jain Saduguru Capital Park, Beside Image Gardens, Madhapur, Hyderabad -  
500081, Telangana

Mail id: cs@curatechnologies.in Mobile No. +918497907290

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**CURA TECHNOLOGIES LIMITED**

**34<sup>TH</sup> ANNUAL REPORT**  
**2024-25**

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**CORPORATE INFORMATION**

**BOARD OF DIRECTORS:**

<b>Sl.no</b>	<b>Name of the Director</b>	<b>Designation</b>	<b>DIN</b>
1.	Ms. Sanjana Lagumavarapu	Managing Director	09440632
2.	Mr. Sangareddypeta Saikiran	Whole-Time Director & CFO	09741325
3.	Mrs. Khushboo Joshi	Independent Director	10864386
4.	Ms. Priyanka Agarwal	Independent Director	03210443
5.	Mr. Prabhakar Reddy Palakolanu	Independent Director	10326142
6.	Mrs. Mounika Pammi	Independent Director	11111376

**CHIEF FINANCIAL OFFICER:**

Mr. Sangareddypeta Saikiran

**COMPANY SECRETARY & COMPLIANCE OFFICER:**

Mrs. Sharvari Swapnil Shinde

**REGISTERED OFFICE:**

Unit No 604 B, Jain Saduguru Capital Park, Beside Image Gardens, Madhapur, Shaikpet,  
Hyderabad, 500081 Telangana

Ph: +91 8497907290

[cs@curatechnologies.in](mailto:cs@curatechnologies.in)

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**STATUTORY AUDITORS:**

Pundarikashyam and Associates  
Chartered Accountants  
1-8-435/436, 2nd Floor, Durga Towers,  
Beside Rasoolpura Metro Station,  
Begumpet, Hyderabad - 500016.

**CIN: L84120TG1991PLC013479**

**BANKERS:**

SBI Bank Limited  
Income Tax colony, Banjara Hills Branch  
Hyderabad, Telangana

**AUDIT COMMITTEE:**

- |                                   |   |          |
|-----------------------------------|---|----------|
| 1. Mr. Prabhakar Reddy Palakolanu | - | Chairman |
| 2. Mrs. Khushboo Joshi            | - | Member   |
| 3. Mrs. Mounika Pammi             | - | Member   |

**NOMINATION & REMUNERATION COMMITTEE:**

- |                                   |   |          |
|-----------------------------------|---|----------|
| 1. Mr. Prabhakar Reddy Palakolanu | - | Chairman |
| 2. Mrs. Khushboo Joshi            | - | Member   |
| 3. Mrs. Mounika Pammi             | - | Member   |

**STAKEHOLDER RELATIONSHIP COMMITTEE:**

- |                                   |   |          |
|-----------------------------------|---|----------|
| 1. Mr. Prabhakar Reddy Palakolanu | - | Chairman |
| 2. Mrs. Khushboo Joshi            | - | Member   |
| 3. Mrs. Mounika Pammi             | - | Member   |

**INDEPENDENT DIRECTORS COMMITTEE:**

1. Mr. Prabhakar Reddy Palakolanu
2. Ms. Priyanka Agarwal
3. Mrs. Khushboo Joshi
4. Mrs. Mounika Pammi

# **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

**LISTING:** BSE Limited and National Stock Exchange of India Limited

**REGISTRAR & SHARE TRANSFER AGENTS:**

Venture Capital & Corporate Investments Private Limited

12-10-167, Bharat Nagar,

Hyderabad – 500018 Telangana Tel No.: 04023818475 /23868023 Fax: 040-23868024

E-mail: info@vccilindia.com

**CONTACT DETAILS:**

**E-Mail:** [cs@curatechnologies.in](mailto:cs@curatechnologies.in)

**Phone :** +91-849790729

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**NOTICE**

Notice is hereby given that the 34<sup>th</sup> Annual General Meeting of the members of the Cura Technologies Limited will be held on Monday, the 29<sup>th</sup> day of September, 2025 at 3:00 p.m. through Video Conferencing/ Other Audio Visual Means (OAVM) to transact the following Business:

**ORDINARY BUSINESS:**

1. To receive, consider and adopt the Audited Balance Sheet as at March 31, 2025 and the Statement of Profit & Loss and cash flow statement for the year ended on that date together with the Notes attached thereto, along with the Reports of Auditors and Directors thereon.
2. To appoint a director in place of Ms. Sanjana Lagumavarapu who retires by rotation and being eligible, offers herself for re-appointment.

**SPECIAL BUSINESS:**

3. **APPOINTMENT OF MRS. KHUSHBOO JOSHI (DIN: 10864386) AS AN INDEPENDENT DIRECTOR OF THE COMPANY**

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

“**RESOLVED THAT** pursuant to the provisions of Sections 149, 150, 152 and Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 (‘the Act’) read with rules made thereunder, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and other applicable laws and the provisions of the Articles of Association of the Company and pursuant to recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors of the Company, Mrs. Khushboo Joshi (DIN: 10864386), who has submitted a declaration that she meets the criteria of independence as provided in Section 149(6) of the Companies Act, 2013 and the rules made thereunder and who was appointed as an Additional Director (Independent category) of the Company to hold office up to the date of Annual General Meeting or the last date on which the annual general meeting should have been held, whichever is earlier be and is hereby appointed as an Independent Director of the Company, not liable to retire by rotation, for a term of 5 years effective from 07.01.2025 to 06.01.2030 (both dates inclusive).”

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

**“RESOLVED FURTHER THAT** the Board be and is hereby authorized to sign and execute all such documents and papers as may be required for the purpose and file necessary e-form with the Registrar of Companies and to do all such acts, deeds and things as may be considered expedient and necessary in this regard.”

#### **4. APPOINTMENT OF MRS. MOUNIKA PAMMI (DIN: 11111376) AS AN INDEPENDENT DIRECTOR OF THE COMPANY**

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

**“RESOLVED THAT** pursuant to the provisions of Sections 149, 150, 152, Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with rules made thereunder, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and other applicable laws and the provisions of the Articles of Association of the Company and pursuant to recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors of the Company, Mrs. Mounika Pammi (DIN: 11111376), who has submitted a declaration that she meets the criteria of independence as provided in Section 149(6) of the Companies Act, 2013 and the rules made thereunder and who was appointed as an Additional Director (Independent category) of the Company to hold office up to the date of this Annual General Meeting or the last date on which the annual general meeting should have been held, whichever is earlier, be and is hereby appointed as an Independent Director of the Company, not liable to retire by rotation, for a term of 5 years effective from 30.05.2025 to 29.05.2030 (both dates inclusive).”

**“RESOLVED FURTHER THAT** the Board be and is hereby authorized to sign and execute all such documents and papers as may be required for the purpose and file necessary e-form with the Registrar of Companies and to do all such acts, deeds and things as may be considered expedient and necessary in this regard.”

**For and on behalf of the Board  
Cura Technologies Limited**

**Place: Hyderabad  
Date: 04.09.2025**

**Sangareddypeta Saikiran  
Whole-time director and CFO  
(DIN: 09741325)**

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**NOTES:**

1. In pursuance of Regulation 36 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings, details in respect of the Directors seeking appointment/ re-appointment at the AGM, form part of this Notice.
2. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and The Ministry of Corporate Affairs (“MCA”) has vide its General Circular No. 09/2024 dated 19.09.2024 and SEBI vide its circular SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133, dated October 3, 2024 (hereinafter collectively referred to as “the Circulars”), in relation to “Clarification on holding of General Meeting through video conferencing (VC) or other audio visual means (OAVM)”, permitted the holding of the Annual General Meeting (“AGM”) through VC/OAVM, without the physical presence of the Members at a common venue. In compliance with the said Circulars, the AGM of the Company is being held through VC/OAVM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized e-Voting’s agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by CDSL.
3. The Deemed Venue of the 34th AGM of the Company shall be its Registered Office.
4. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to at-least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
5. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013.
6. Pursuant to the provisions of the Act, a Member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

proxies by the Members will not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed to this Notice.

7. Corporate/institutional Members (i.e. other than individuals, HUF, NRI, etc.) are required to send a scanned copy (PDF/ JPG format) of the relevant Board Resolution/Authority Letter / Power of Attorney etc. together with attested specimen signature of the duly authorised signatory(ies) who is /are authorised to vote, to the Scrutinizer through e-mail at [cs@curatechnologies.in](mailto:cs@curatechnologies.in) .
8. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at [www.curatechnologies.in](http://www.curatechnologies.in). The Notice along with Annual Report can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively. The AGM Notice along with Annual Report is also disseminated on the website of CDSL (agency for providing the Remote e-Voting facility and e-voting system during the AGM) i.e. [www.evotingindia.com](http://www.evotingindia.com).
9. The AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated April 8, 2020 and MCA Circular No. 17/2020 dated April 13, 2020 and MCA Circular No. 20/2020 dated May 05, 2020.
10. Members holding shares in the same name under different ledger folios are requested to apply for Consolidation of such folios and send the relevant share certificates to Venture Capital Corporate Investments Private Limited., Share Transfer Agents of the Company for their doing the needful.
11. Members are requested to send their queries at least 5 days before the date of meeting so that information can be made available at the meeting.
12. In respect of shares held in physical mode, all shareholders are requested to intimate changes, if any, in their registered address immediately to the registrar and share transfer agent of the Company and correspond with them directly regarding share transfer/transmission /transposition, Demat/Remat, change of address, issue of duplicate shares certificates, ECS and nomination facility.
13. In terms of Section 72 of the Companies Act, 2013, a member of the Company may nominate a person on whom the shares held by him/her shall vest in the event of his/her death. Members desirous of availing this facility may submit nomination in prescribed Form-SH-13 to the Company/RTA in case shares are held in physical form, and to their respective depository participant, if held in electronic form.
14. Members holding shares in the electronic form are requested to inform any changes in address/bank mandate directly to their respective Depository Participants.

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

15. The company has appointed M/s. Vivek Surana & Associates, Practicing Company Secretaries, as scrutinizer of the company to scrutinize the voting process.
16. Since securities of the Company are traded compulsorily in dematerialized form as per SEBI mandate, members holding shares in physical form are requested to get their shares dematerialized at the earliest.
17. In compliance with the MCA Circulars and SEBI Circular dated January 15, 2021 as aforesaid, Notice of the AGM along with the Annual Report 2024-25 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/Depositories.
18. Since the AGM will be held through VC / OAVM, the Route Map is not annexed in this Notice.
19. The Members can join the e-AGM 15 minutes before the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice.
20. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of Contracts or arrangements in which the Directors are interested under Section 189 of the Companies Act, 2013, will be available for inspection at the AGM.

### **21. THE INTRUCTIONS OF SHAREHOLDERS FOR E-VOTING AND JOINING VIRTUAL MEETINGS ARE AS UNDER:**

- (i) The voting period begins on 26.09.2025 at 9.00 a.m. and ends on 28.09.2025 at 5.00 p.m. During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of 22.09.2025 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (iii) Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020**, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholder's/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

## CURA TECHNOLOGIES LIMITED

**CIN: L84120TG1991PLC013479**

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to **all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants**. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

### **Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.**

- (iv) In terms of SEBI circular no. **SEBI/HO/CFD/CMD/CIR/P/2020/242** dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to above said SEBI Circular, Login method for e-Voting and joining virtual meetings **for Individual shareholders holding securities in Demat mode CDSL/NSDL** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with <b>CDSL Depository</b>	<ol style="list-style-type: none"><li>1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit cdsi website <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on login icon &amp; My Easi New (Token) Tab.</li><li>2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.</li><li>3) If the user is not registered for Easi/Easiest, option to register is available at cdsi website <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on login &amp; My Easi New (Token) Tab and then click on registration option.</li></ol>

## CURA TECHNOLOGIES LIMITED

CIN: L84120TG1991PLC013479

	<p>4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page. The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.</p>
<p>Individual Shareholders holding securities in demat mode with NSDL Depository</p>	<ol style="list-style-type: none"><li>1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a> either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li><li>2) If the user is not registered for IDeAS e-Services, option to register is available at <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a>. Select “Register Online for IDeAS “Portal or click at <a href="https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</a></li><li>3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsdl.com/">https://www.evoting.nsdl.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting</li></ol>

## CURA TECHNOLOGIES LIMITED

**CIN: L84120TG1991PLC013479**

	<p>4) For OTP based login you can click on <a href="https://eservices.nsd.com/SecureWeb/evoting/evotinglogin.jsp">https://eservices.nsd.com/SecureWeb/evoting/evotinglogin.jsp</a>. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on <b>company name or e-Voting service provider name</b> and you will be re-directed to <b>e-Voting service provider website</b> for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p>
<p>Individual Shareholders (holding securities in demat mode) login through their <b>Depository Participants (DP)</b></p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p>

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with <b>CDSL</b>	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at toll free no. 1800 21 09911
Individual Shareholders holding securities in Demat mode with <b>NSDL</b>	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.co.in">evoting@nsdl.co.in</a> or call at : 022 - 4886 7000 and 022 - 2499 7000

**Step 2:** Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

(v) Login method for e-Voting and joining virtual meetings for **Physical shareholders and shareholders other than individual holding in Demat form.**

1) The shareholders should log on to the e-voting website [www.evotingindia.com](http://www.evotingindia.com).

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

- 2) Click on “Shareholders” module.
- 3) Now enter your User ID
  - a. For CDSL: 16 digits beneficiary ID,
  - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
  - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to [www.evotingindia.com](http://www.evotingindia.com) and voted on an earlier e-voting of any company, then your existing password is to be used.
- 6) If you are a first-time user follow the steps given below:

	<b>For Physical shareholders and other than individual shareholders holding shares in Demat.</b>
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"><li>• Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.</li></ul>
Dividend Bank Details <b>OR</b> Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. <ol style="list-style-type: none"><li>1. If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.</li></ol>

- (vi) After entering these details appropriately, click on “SUBMIT” tab.
- (vii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

## CURA TECHNOLOGIES LIMITED

CIN: L84120TG1991PLC013479

- (viii) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (ix) Click on the EVSN for the relevant CURA TECHNOOGIES LIMITED on which you choose to vote.
- (x) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xi) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (xii) After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (xiii) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xiv) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xv) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xvi) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.
- (xvii) **Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.**
- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to [www.evotingindia.com](http://www.evotingindia.com) and register themselves in the “Corporates” module.
  - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com).
  - After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
  - The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
  - It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

- Alternatively, Non Individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; cs@curatechnologies.in (designated email address by company), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

**INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:**

1. The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least **5 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at cs@curatechnologies.in. The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance **5 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at cs@curatechnologies.in. These queries will be replied to by the company suitably by email.
8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

9. Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
10. If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders may be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

**PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.**

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to **Company/RTA email id**.
2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP)
3. **For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.**

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or contact at toll free no. 1800 21 09911

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL, ) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or call toll free no. 1800 21 09911.

**For and on behalf of the Board**  
**Cura Technologies Limited**

**Place: Hyderabad**  
**Date: 04.09.2025**

**Sangareddypeta Saikiran**  
**Whole-time director and CFO**  
**(DIN: 09741325)**

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**Annexure**

**As required under Regulation 36 (3) of the SEBI (LODR), Regulations, 2015, brief particulars of the Directors seeking appointment/re-appointment are given as under:**

Name of the Director	Ms. Sanjana Lagumavarapu
Date of Birth and Age	24/05/1980 & 45 years
Brief Resume including Qualification and Experience	Ms. Sanjana Lagumavarapu is experienced in HR, accounts and administration works
Date of First Appointment in the Board	06.10.2023
Expertise in specific functional areas	Accounts and Administration
Shareholding in the Company	20,000 equity shares
Relationship with other Directors, Key Managerial Personnel	Nil
Directorship in other Companies	Nil
Membership / Chairmanship in committee of the other companies	Nil
Names of Listed entities in which the person also holds the Directorship and the membership of Committees of the Board along with listed entities from which the person has resigned in the past three years	Nil
skills and capabilities required for the role and the manner in which the proposed person meets such requirements	Not Applicable

**For and on behalf of the Board**  
**Cura Technologies Limited**

**Place: Hyderabad**  
**Date: 04.09.2025**

**Sangareddypeta Saikiran**  
**Whole-time director and CFO**  
**(DIN: 09741325)**

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013 AND**  
**REGULATIONS OF SEBI (LODR), REGULATIONS, 2015**

**ITEM NO.3: APPOINTMENT OF MRS. KHUSHBOO JOSHI (DIN: 10864386) AS AN INDEPENDENT DIRECTOR OF THE COMPANY**

Pursuant to Section 161 of Companies Act, 2013, the appointment of Additional director (Independent category) shall be regularized at the next Annual General Meeting or the last date on which the annual general meeting should have been held, whichever is earlier.

Accordingly, Mrs. Khushboo Joshi who was appointed as an Additional Director of the Company on 07.01.2025 in terms of Section 161 (1) of the Companies Act, 2013 and provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018 in the category of 'Non- Executive Independent Director' is required to be regularized at the earliest but not later than this Annual General meeting as an Independent Director of the company by way of a Special Resolution.

The Company has received a notice in writing from a member under Section 160 of the Act proposing the candidature of Mrs. Khushboo Joshi for the office of Director of the Company. She has given her consent to act as a Director and is not disqualified from being appointed as a Director in terms of Section 164 of the Act.

Mrs. Khushboo Joshi has also confirmed that she is not debarred from holding the office of Director by virtue of any SEBI Order or any such authority pursuant to circulars dated June 20, 2018 issued by Exchanges pertaining to enforcement of SEBI Orders regarding appointment of Directors by the listed companies.

Mrs. Khushboo Joshi has also confirmed that she is in compliance with Rules 6(1) and 6(2) of the Companies (Appointment and Qualifications of Directors) Rules, 2014, with respect to her registration with the data bank of Independent Directors maintained by the Indian Institute of Corporate Affairs ('IICA').

The Board is of the opinion that Mrs. Khushboo Joshi continues to possess the identified core skills, expertise and competencies fundamental for effective functioning in her role as an Independent Director of the Company and her association would be of beneficial to the Company.

Accordingly, in order to ensure compliance with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018 and Sections

## CURA TECHNOLOGIES LIMITED

**CIN: L84120TG1991PLC013479**

149, 150, 152 of the Companies Act, 2013 read with Rules made thereunder and Schedule IV of the Act, it is proposed that approval of the shareholders by way of a Special Resolution be accorded for the appointment of Mrs. Khushboo Joshi as 'Non-executive Independent Director' for a term of 5 consecutive years commencing from the date of her appointment as an Additional Director i.e. w.e.f. 07.01.2025 to 06.01.2030.

Mrs. Khushboo Joshi is a Member of the Institute of Company Secretaries of India and has over 10 years of experience. She holds expertise in Secretarial Services, Advisory and Risk Management Consulting. She is currently working as a whole-time Company Secretary in Kisaan Parivar Industries Limited.

The NRC taking into consideration the skills, expertise and competencies required for the Board in the context of the business and sectors of the Company a recommended to the Board in view of her rich experience in the above-mentioned areas and special skill set and capabilities.

The Board of Directors recommends the passing of the above resolution as a Special Resolution as set out in the item no. 3 of the notice for appointment of Mrs. Khushboo Joshi as an Independent director.

Save and except Mrs. Khushboo Joshi, Independent Director, being the appointee, none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned directly or indirectly, financially or otherwise, in the resolution.

**As required under Regulation 36 (3) of the SEBI (LODR), Regulations, 2015, brief particulars of the Directors seeking appointment/re-appointment are given as under:**

Name of the Director	Mrs. Khushboo Joshi
Date of Birth and Age	17.12.1985 and 39 years
Brief Resume including Qualification and Experience	Mrs. Khushboo Joshi is a Member of the Institute of Company Secretaries of India and has over 10 years of extensive experience. She holds expertise in Secretarial Services, Advisory and Risk Management Consulting. She is currently working as a whole-time Company Secretary in Kisaan Parivar Industries Limited. Qualification: Company Secretary
Details of Remuneration paid and last drawn remuneration	Nil
Date of First Appointment in the Board	07.01.2025
Expertise in specific functional areas	Secretarial Services, Advisory and Risk Management Consulting

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

Shareholding in the Company	Nil
Relationship with other Directors, Key Managerial Personnel	Nil
Directorship in other Companies	1
Membership / Chairmanship in committee of the other companies	4
Names of Listed entities in which the person also holds the Directorship and the membership of Committees of the Board along with listed entities from which the person has resigned in the past three years	Variman Global Enterprises Limited Audit Committee: Member Nomination and Remuneration Committee: Member Stakeholders Relationship Committee: Member Risk Management Committee: Member
skills and capabilities required for the role and the manner in which the proposed person meets such requirements	The Director is having required Skills and capable of handling the role as Independent Director in the Company in view of her experience.

**ITEM NO.4: APPOINTMENT OF MRS. MOUNIKA PAMMI (DIN: 11111376) AS AN INDEPENDENT DIRECTOR OF THE COMPANY**

Pursuant to Section 161 of Companies Act, 2013, the appointment of Additional director (Independent category) shall be regularized at the next Annual General Meeting or the last date on which the annual general meeting should have been held, whichever is earlier.

Accordingly, Mrs. Mounika Pammi (DIN: 11111376) who was appointed as an Additional Director of the Company on 07.01.2025 in terms of Section 161 (1) of the Companies Act, 2013 and provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018 in the category of 'Non- Executive Independent Director' is required to be regularized at the earliest but not later than this Annual Ge as an Independent Director of the company by way of a Special Resolution.

The Company has received a notice in writing from a member under Section 160 of the Act proposing the candidature of Mrs. Mounika Pammi for the office of Director of the Company. She has given her consent to act as a Director and is not disqualified from being appointed as a Director in terms of Section 164 of the Act.

Accordingly, in order to ensure compliance with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018 and Sections 149, 150, 152 of the Companies Act, 2013 read with Rules made thereunder and Schedule IV of the

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

Act, it is proposed that approval of the shareholders by way of a Special Resolution be accorded for the appointment of Mrs. Mounika Pammi as 'Non-executive Independent Director' for a term of 5 consecutive years commencing from the date of her appointment as an Additional Director i.e. w.e.f. 30.05.2025 to 29.05.2030.

Mrs. Mounika Pammi is a seasoned professional with over 15 years of leadership experience across marketing, insurance, administration, CSR, and strategic consulting. She holds an MBA in Marketing and has led business transformation initiatives with a strong focus on operational efficiency and governance. As a former MD of MNRG Technologies, she brings deep strategic insight and Board level acumen. Her expertise spans corporate strategy, stakeholder engagement, and sustainable development.

The NRC taking into consideration the skills, expertise and competencies required for the Board in the context of the business and sectors of the Company a recommended to the Board in view of her rich experience in the above-mentioned areas and special skill set and capabilities.

The Board is of the opinion that Mrs. Mounika Pammi continues to possess the identified core skills, expertise and competencies fundamental for effective functioning in her role as an Independent Director of the Company and her association would be of beneficial to the Company.

Mrs. Mounika Pammi has also confirmed that she is not debarred from holding the office of Director by virtue of any SEBI Order or any such authority pursuant to circulars dated June 20, 2018 issued by BSE Limited pertaining to enforcement of SEBI Orders regarding appointment of Directors by the listed companies.

Mrs. Mounika Pammi has also confirmed that she is in compliance with Rules 6(1) and 6(2) of the Companies (Appointment and Qualifications of Directors) Rules, 2014, with respect to her registration with the data bank of Independent Directors maintained by the Indian Institute of Corporate Affairs ('IICA').

In the opinion of the Board, Mrs. Mounika Pammi fulfils the conditions specified in the Act, rules thereunder and the SEBI Listing Regulations for appointment as an Independent Director and that she is independent of the Management.

The Board of Directors recommends the passing of the above resolution as a Special Resolution as set out in the item no. 4 of the notice for appointment of Mrs. Mounika Pammi as an Independent director.

Save and except Mrs. Mounika Pammi, Independent Director, being the appointee, none of the other

## CURA TECHNOLOGIES LIMITED

**CIN: L84120TG1991PLC013479**

Directors/Key Managerial Personnel and their relatives is in any way interested or concerned directly or indirectly, financially or otherwise, in the resolution.

**As required under Regulation 36 (3) of the SEBI (LODR), Regulations, 2015, brief particulars of the Directors seeking appointment/re-appointment are given as under:**

Name of the Director	Mrs. Mounika Pammi			
Date of Birth and Age	17.06.1980 and 45 years			
Brief Resume including ion and Experience	Mrs. Mounika Pammi is a Mrs. Pammi Mounika is a seasoned  professional with over 15 years of leadership experience across marketing, insurance, administration, CSR, and strategic consulting. She holds an MBA in  Marketing and has led business transformation initiatives with a strong focus on _ operational efficiency and governance. As a former MD of MNRG Technologies, she brings deep strategic insight and Board level acumen. Her expertise spans corporate strategy, stakeholder engagement, and sustainable development Qualification: MBA			
Details of Remuneration paid and last drawn remuneration	Nil			
Date of First Appointment in the Board	30.05.2025			
Expertise in specific functional areas	Leadership experience across marketing, insurance, administration, CSR, and strategic consulting			
Shareholding in the Company	Nil			
Relationship with other Directors, Key Managerial Personnel	Nil			
Directorship in other Companies	7			
Membership / Chairmanship in committee of the other companies	<b>Name of the Company</b>	<b>Audit Committee</b>	<b>Nomination and Remuneration Committee</b>	<b>Stakeholders Relationship Committee</b>
Names of Listed entities in which the person also holds the Directorship and the membership of Committees of the Board along with listed entities from which the person has resigned in the past three years	Midland Polymers Limited	Member	Member	Member
	Bandaram Pharma Packtech Limited	Member	Member	Member

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

	Ortin Global Limited	Member	Member	Member
	Variman Global Enterprises Limited	-	-	-
	Soma Papers Industries Limited	Chairperson	Member	Chairperson
	Aion-Tech Solutions Limited	-	-	-
skills and capabilities required for the role and the manner in which the proposed person meets such requirements	The Director is having required Skills and capable of handling the role as Independent Director in the Company in view of her rich experience in Business			

**For and on behalf of the Board**  
**Cura Technologies Limited**

**Place: Hyderabad**  
**Date: 04.09.2025**

**Sangareddypeta Saikiran**  
**Whole-time director and CFO**  
**(DIN: 09741325)**

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**DIRECTORS' REPORT**

**To**  
**The Members of**  
**Cura Technologies Limited**

The Directors have pleasure in presenting before you the Directors' Report on the Business and Operations of the Company together with the audited Financial Statements for the year ended 31<sup>st</sup> March, 2025.

**1. CHANGE IN MANAGEMENT ETC PURSUANT TO THE RESOLUTION PLAN APPROVED BY THE HON'BLE NCLT, HYDERABAD BENCH VIDE ITS ORDERS DATED 14.09.2023:**

The Hon'ble National Company Law Tribunal ("NCLT"), Hyderabad Bench, vide Order dated 16.03.2022 ("Insolvency Commencement Order") had initiated Corporate Insolvency Resolution Process ("CIRP") against the Company, based on the petition filed by the Financial Creditor under Section 7 of the Insolvency and Bankruptcy Code, 2016 ("the Code") and has approved the Resolution Plan vide its Orders dated 14.09.2023.

**The Company has completed the corporate actions including the following as envisaged in the approved Resolution Plan in addition to various compliances during the year under review:**

a. Change of management and constitution of new Board of directors to administer the affairs of the Company and alteration of Objects Clause of the MOA.

**b. Reduction of Capital:**

- 100% (Hundred Percent) of the total paid-up equity share capital held by the promoters of the Company comprising of 27,48,640 (Twenty-Seven Lakhs Forty-Eight Thousand Six Hundred and Forty) equity shares has been cancelled and reduced.
- Reduction of 95% (Ninety-Five Percent) of the total paid-up equity share capital held by the non-promoters of the Company comprising of 68,05,960 (Sixty-Eight Lakhs Five Thousand Nine Hundred and Sixty) equity shares have become 3,40,298 (Three Lakh Forty Thousand Two Hundred and Ninety-Eight) equity shares. The Company has received the Trading approval from both the Stock Exchanges for 3,40,298 Equity Shares on 19.03.2025 and the shares are available for trading effective from 21.03.2025.

c. Allotment of 23,59,702 equity shares of Rs. 10/- each to resolution applicant and other strategic investors and Allotment of 72,00,000 equity shares of Rs. 10/- each to the shareholders of Catalog IT Solutions Private Limited on account of merger and the Company has received the Trading approval from both the Stock Exchanges.

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**2. FINANCIAL SUMMARY/HIGHLIGHTS:**

The performance of the Company during the year has been as under:

(Rs.in lakhs)

<b>Particulars</b>	<b>FY 2024-25</b>	<b>FY 2023-24</b>
Revenue from Operations	-	-
Other Income (Including Exceptional Items)	-	-
Total Expenses	66.29	94.07
Profit Before Tax	(66.29)	(94.07)
Less: Provision for Taxation	--	--
Profit / (Loss) After Tax	(66.29)	(94.07)
Other Comprehensive Income	--	--
Total Comprehensive Income	(66.29)	(94.08)
Earning per Equity Share		
Basic	(2.32)	(4.83)
Diluted (in Rs.)	(2.32)	(4.83)

**3. REVIEW OF OPERATIONS:**

During the Year under the review, there were no Operations in the Company and has incurred a net loss of Rs. 66.29 Lakhs as against the Nil income and net loss of Rs. 94.07 Lakhs in the previous financial year ending 31.03.2024

As the Company is under the process of revival, the Company has commenced operations and generated a revenue of around Rs. 14 lakhs during the 1<sup>st</sup> Quarter of FY 2025-26.

**4. BUSINESS UPDATE AND STATE OF COMPANY'S AFFAIRS:**

The information on Company's affairs and related aspects is provided under Management Discussion and Analysis report, which has been prepared, inter-alia, in compliance with Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) regulations, 2015 and forms part of this Report.

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**5. RESERVES:**

Pursuant to provisions of Section 134 (3) (j) of the Companies Act, 2013, the company has not proposed to transfer any amount to general reserves account of the company during the year under review.

The closing balance of reserves, including retained earnings, of the Company as at March, 31<sup>st</sup> 2025 is Rs. (203.16) Lakhs.

**6. DIVIDEND:**

Your Directors have decided not to recommend any dividend for the year 2024-25.

**7. CHANGE IN THE NATURE OF THE BUSINESS, IF ANY:**

During the period under review and the date of Directors' Report there was no change in the nature of Business.

**8. MATERIAL CHANGES AND COMMITMENTS:**

There were no material changes and commitments affecting financial position of the company between 31<sup>st</sup> March 2025 and the date of Board's Report (i.e. 04.09.2025).

**9. REVISION OF FINANCIAL STATEMENTS:**

There was no revision of the financial statements for the year under review.

**10. AUTHORISED AND PAID-UP CAPITAL OF THE COMPANY:**

As on 31.03.2025, the Authorised share capital of the Company is Rs. 10,00,00,000/- divided into 10,00,000 equity shares of Rs.10/- each and subscribed and paid-up capital of the Company is Rs. 9,15,00,000/- divided into 91,50,000 Equity shares of Rs.10/- each.

As on date, the paid-up capital of the Company is Rs. 9,99,00,000/- divided into 99,90,000 Equity shares of Rs.10/- each.

The following changes in Paid-up share capital from 01.04.2024 till date are as follows:

<b>Date of allotment</b>	<b>Particulars</b>	<b>Increase in paid-up capital</b>
13.02.2025	Allotment of 72,00,000 equity shares	Increase in paid up capital

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

	pursuant to the scheme of arrangement as per the resolution plan approved by Hon'ble NCLT, Hyderabad Bench vide Order dated 14.09.2023	from Rs. 1,95,00,000/- to Rs. 9,15,00,000/-.
21.06.2025	Allotment of 7,50,000 equity shares to strategic financial investor on cash basis as per the resolution plan and	increase in paid up capital from Rs. 9,15,00,000/- to Rs. 9,90,00,000/-

**11. APPOINTMENT / RE-APPOINTMENT / RESIGNATION / RETIREMENT OF DIRECTORS /CEO/  
CFO AND KEY MANAGERIAL PERSONNEL:**

**a.) Appointments:**

- Appointment of Mrs. Sharvari Shinde as Company Secretary and Compliance Officer of the Company w.e.f., 18.09.2024.
- Appointment of Mrs. Khushboo Joshi as an Additional Director (Independent) of the Company w.e.f. 07.01.2025.
- Appointment of Mrs. Mounika Pammi as an Additional Director (Independent) of the Company w.e.f. 30.05.2025.

**b.) Resignations:**

- Resignation of Mr. Nitesh Kumar Sharma as Company Secretary and Compliance Officer of the Company w.e.f., 18.09.2024.
- Resignation of Mr. K. Rajasekhara Reddy as an Independent Director of the Company w.e.f. 07.01.2025.

The Board places on record sincere appreciation for the services rendered by the above said Director/KMP during their tenure.

**12. DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS:**

The Company has received declarations from all the Independent Directors of the Company confirming that they meet with both the criteria of independence as prescribed under sub-section (6) of Section 149 of the Companies Act, 2013 and under Reg.16(1)(b) read with Reg. 25 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

In compliance with Rule 6 of Companies (Appointment and Qualification of Directors) Rules, 2014, all the PIDs of the Company have registered themselves with the India Institute of Corporate Affairs (IICA), Manesar and have included their names in the databank of Independent Directors within the statutory timeline.

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

The Independent Directors have also confirmed that they have complied with Schedule IV of the Act and the Company's Code of Conduct. In terms of Reg. 25(8) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the Independent Directors have confirmed that they are not aware of any circumstance or situation, which exists or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgement and without any external influence.

During the year, Independent Directors of the Company had no pecuniary relationship or transactions with the Company, other than sitting fees, commission and reimbursement of expenses incurred by them for the purpose of attending meetings of the Board of Directors and Committee(s).

**13. BOARD MEETINGS:**

The Board of Directors duly met eight (8) times during the year on 06.04.2024, 27.05.2024, 13.08.2024, 18.09.2024, 12.11.2024, 07.01.2025, 13.02.2025 and 12.03.2025 and in respect of which meetings, proper notices were given and the proceedings were properly recorded and signed in the Minutes Book maintained for the purpose.

**14. BOARD EVALUATION:**

The Board of Directors has carried out an annual evaluation of its own performance, Board committees, and individual directors pursuant to the provisions of the Companies Act, 2013 and SEBI Listing Regulations.

The performance of the Board was evaluated by the Board after seeking inputs from all the directors on the basis of criteria such as the Board composition and structure, effectiveness of Board processes, information and functioning, etc.

The performance of the committees was evaluated by the Board after seeking inputs from the committee members on the basis of criteria such as the composition of committees, effectiveness of committee meetings, etc.

A separate meeting of independent directors was conducted on 13.02.2025 to evaluate the performance of non-independent directors, the Board as a whole and the Chairman of the Company, taking into account the views of executive directors and non-executive directors.

The Board reviewed the performance of individual directors on the basis of criteria such as the contribution of the individual director to the Board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings,

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

etc. Performance evaluation of independent directors was done by the entire Board, excluding the independent director being evaluated.

### **15. STATEMENT SHOWING THE NAMES OF THE TOP TEN EMPLOYEES IN TERMS OF REMUNERATION DRAWN AND THE NAME OF EVERY EMPLOYEE AS PER RULE 5(2) & (3) OF THE COMPANIES (APPOINTMENT & REMUNERATION) RULES, 2014:**

A table containing the particulars in accordance with the provisions of Section 197(12) of the Act, read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is appended as **Annexure IV (a)** to this Report.

A statement showing the names of the top ten employees in terms of remuneration drawn and the name of every employee is annexed to this Annual report as **Annexure IV (b)**.

During the year, none of the employees is drawing a remuneration of Rs.1,02,00,000/- and above per annum or Rs.8,50,000/- and above in aggregate per month, the limits specified under the Section 197(12) of the Companies Act,2013 read with Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

### **16. DIRECTOR'S RESPONSIBILITY STATEMENT:**

Pursuant to the requirement of Section 134(3)(c) and 134(5) of the Companies Act, 2013 and on the basis of explanation given by the executives of the Company and subject to disclosures in the Annual Accounts of the Company from time to time, we state as under:

1. That in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
2. That the Directors have selected such accounting policies and applied them consistently and made judgment and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for that period;
3. That the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
4. That the Directors have prepared the annual accounts on a going concern basis;
5. That the Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

6. That the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

**17. DETAILS OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS:**

The Internal Financial Controls with reference to financial statements as designed and implemented by the Company are adequate. The Company maintains appropriate system of internal control, including monitoring procedures, to ensure that all assets are safeguarded against loss from unauthorized use or disposition. Company policies, guidelines and procedures provide for adequate checks and balances, and are meant to ensure that all transactions are authorized, recorded and reported correctly.

During the period under review, there is no material or serious observations have been noticed for inefficiency or inadequacy of such controls.

Further, details of internal financial control and its adequacy are included in the Management Discussion and Analysis Report which is appended as **Annexure III** and forms part of this Report.

**18. NO FRAUDS REPORTED BY STATUTORY AUDITORS:**

During the Financial Year 2024-25 the Auditors have not reported any matter under section 143(12) of the Companies Act, 2013, therefore no detail is required to be disclosed under section 134(3) (ca) of the Companies Act, 2013.

**19. NAMES OF THE COMPANIES WHICH HAVE BECOME OR CEASED TO BE ITS SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR:**

During the year under review, no Company has become or ceased to become its subsidiary, joint venture or associate Company.

**20. DETAILS RELATING TO DEPOSITS:**

The Company has not accepted any public deposits during the Financial Year ended March 31, 2025 and as such, no amount of principal or interest on public deposits was outstanding as on the date of the balance sheet.

**21. DETAILS OF DEPOSITS NOT IN COMPLIANCE WITH THE REQUIREMENTS OF THE ACT:**

Since the Company has not accepted any deposits during the Financial Year ended March 31, 2025, there has been no non-compliance with the requirements of the Act.

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

Pursuant to the Ministry of Corporate Affairs (MCA) notification dated 22nd January 2019 amending the Companies (Acceptance of Deposits) Rules, 2014, the Company is required to file with the Registrar of Companies (ROC) requisite returns in Form DPT-3 for outstanding receipt of money/loan by the Company, which is not considered as deposits. The Company has complied with this requirement within the prescribed timelines.

### **22. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:**

The Company has not given loans, guarantees or made any investments attracting the provision of Section 186 of the Companies Act, 2013 during the year under review.

### **23. RISK MANAGEMENT POLICY:**

Your Company follows a comprehensive system of Risk Management. Your Company has adopted a procedure for assessment and minimization of probable risks. It ensures that all the risks are timely defined and mitigated in accordance with the well-structured risk management process.

### **24. INVESTOR EDUCATION AND PROTECTION FUND (IEPF):**

Pursuant to the provisions of Section 124 of the Act, Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules") read with the relevant circulars and amendments thereto, the amount of dividend remaining unpaid or unclaimed for a period of seven years from the due date is required to be transferred to the Investor Education and Protection Fund ("IEPF"), constituted by the Central Government.

During the Year, no amount of dividend was unpaid or unclaimed for a period of seven years and therefore no amount is required to be transferred to Investor Education and Provident Fund under the Section 125(1) and Section 125(2) of the Act.

### **25. TRANSFER OF SHARES AND UNPAID/UNCLAIMED AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND (IEPF):**

Pursuant to the provisions of Section 124 of the Act, Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules") read with the relevant circulars and amendments thereto, the amount of dividend remaining unpaid or unclaimed for a period of seven years from the due date is required to be transferred to the Investor Education and Protection Fund ("IEPF"), constituted by the Central Government.

During the Year, no amount of dividend was unpaid or unclaimed for a period of seven years and therefore no amount is required to be transferred to Investor Education and Provident Fund under the Section 125(1) and Section 125(2) of the Act.

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**26. RELATED PARTY TRANSACTIONS:**

Our Company has formulated a policy on related party transactions. This policy deals with the review and approval of related party transactions.

No related party transactions were entered during the financial year. There were no material significant related party transactions made by the Company with the Promoters, Directors, Key Managerial Personnel or the Senior Management which may have a potential conflict with the interest of the Company at large.

Particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013 in the prescribed Form AOC-2 is appended as **Annexure II** which forms part of this Report.

All related party transactions were placed before the Audit Committee/Board for approval. Prior approval of the Audit Committee was obtained for the transactions which are foreseen and are in repetitive in nature. Members may refer to the financial statements which sets out related party disclosures pursuant to IND AS-24.

**27. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO:**

The particulars as prescribed under Section 134(3) (m) of the Companies Act, 2013, is provided hereunder:

**A. Conservation of Energy:**

Your Company's operations are not energy intensive. Adequate measures have been taken to conserve energy wherever possible.

**B. Research & Development and Technology Absorption:**

1. Research and Development (R&D): NIL
2. Technology absorption, adoption and innovation: NIL

**C. Foreign Exchange Earnings and Out Go:**

1. Foreign Exchange Earnings: NIL
2. Foreign Exchange Outgo: NIL

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**28. COMMITTEES:**

- (I) Terms of reference of Audit committee covers all the matters prescribed under Regulation 18 of the Listing Regulations and Section 177 of the Act, 2013.

**A. BRIEF DESCRIPTION OF TERMS OF REFERENCE:**

The terms of reference of the Audit Committee encompasses the requirements of Section 177 of Companies Act, 2013 and as per Regulation 18 of SEBI (LODR) Regulations, 2015 and, inter alia, includes:

- i. Oversight of the listed entity's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- ii. Recommendation for appointment, remuneration and terms of appointment of auditors of the listed entity;
- iii. Approval of payment to statutory auditors for any other services rendered by the statutory auditors;
- iv. Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the Board for approval, with particular reference to:
  - a. Matters required to be included in the director's responsibility statement to be included in the Board's report in terms of clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013;
  - b. Changes, if any, in accounting policies and practices and reasons for the same;
  - c. Major accounting entries involving estimates based on the exercise of judgment by management;
  - d. Significant adjustments made in the financial statements arising out of audit findings;
  - e. Compliance with listing and other legal requirements relating to financial statements;
  - f. Disclosure of any related party transactions;
  - g. Modified opinion(s) in the draft audit report;
- v. Reviewing, with the management, the quarterly financial statements before submission to the Board for approval;

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

- vi. Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public issue or rights issue or preferential issue or qualified institutions placement, and making appropriate recommendations to the Board to take up steps in this matter;
- vii. Reviewing and monitoring the auditor's independence and performance, and effectiveness of audit process;
- viii. Approval or any subsequent modification of transactions of the listed entity with related parties;
- ix. Scrutiny of inter-corporate loans and investments;
- x. Valuation of undertakings or assets of the listed entity, wherever it is necessary;
- xi. Evaluation of internal financial controls and risk management systems;
- xii. Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;
- xiii. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- xiv. Discussion with internal auditors of any significant findings and follow up there on;
- xv. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board;
- xvi. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- xvii. To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- xviii. To review the functioning of the whistle blower mechanism;
- xix. Approval of appointment of chief financial officer after assessing the qualifications,

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

experience and background, etc. of the candidate;

- xx. Carrying out any other function as is mentioned in the terms of reference of the audit committee.
- xxi. Reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision.
- xxii. Consider and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders.
- xxiii. Carrying out any other function as may be referred to the Committee by the Board.
- xxiv. Authority to review / investigate into any matter covered by Section 177 of the Companies Act, 2013 and matters specified in Part C of Schedule II of the Listing Regulations.

**B. THE AUDIT COMMITTEE SHALL MANDATORILY REVIEW THE FOLLOWING INFORMATION:**

- i. Management discussion and analysis of financial condition and results of operations;
- ii. Management letters / letters of internal control weaknesses issued by the statutory auditors;
- iii. Internal audit reports relating to internal control weaknesses; and
- iv. The appointment, removal and terms of remuneration of the chief internal auditor shall be subject to review by the audit committee.
- v. Statement of deviations:
  - Quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1).
  - Annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7).

## CURA TECHNOLOGIES LIMITED

CIN: L84120TG1991PLC013479

### C. COMPOSITION, MEETINGS & ATTENDANCE:

The Audit Committee duly met Four (04) times during the financial year from 1st April 2024 to 31st March 2025. The date on which the meetings were held are 27.05.2024, 13.08.2024, 12.11.2024 and 13.02.2025.

Name	Designation	Category	No. of Meetings held during the tenure	No. of meetings attended
Mr. PrabhakarReddy Palakolanu	Chairperson	Independent Director	4	4
*Mr. K. Rajasekhara Reddy	Member	Independent Director	3	3
Mr. Sangareddypeta Saikiran	Member	Whole-time Director	4	4
Mrs. Khushboo Joshi**	Member	Independent Director	1	1
Mrs. Mounika Pammi#	Member	Independent Director	-	-

\*Resigned w.e.f. 07.01.2025

\*\* Appointed w.e.f. 07.01.2025

# Appointed w.e.f. 30.05.2025

During the year, all recommendations of Audit Committee were approved by the Board of Directors.

#### (I). NOMINATION AND REMUNERATION COMMITTEE

##### A. BRIEF DESCRIPTION OF TERMS OF REFERENCE

- i. Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board of directors a policy relating to, the remuneration of the directors, key managerial personnel and other employees;
- ii. For every appointment of an independent director, the Nomination and Remuneration

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the Board for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:

- a. use the services of an external agencies, if required;
  - b. consider candidates from a wide range of backgrounds, having due regard to diversity; and
  - c. consider the time commitments of the candidates.
- iii. Formulation of criteria for evaluation of performance of independent directors and the Board of directors;
- iv. Devising a policy on diversity of Board of directors;
- v. Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board of directors their appointment and removal.
- vi. Whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.

**B. COMPOSITION OF THE COMMITTEE, MEETINGS AND ATTENDANCE DURING THE YEAR:**

The Nomination and Remuneration Committee duly met three (03) times during the financial year from 1st April 2024 to 31st March 2025. The date on which the meetings were held are 18.09.2024, 07.01.2025 and 13.02.2025.

Name	Designation	category	No. of Meetings held during the tenure	No. of meetings attended
Mr. K Rajasekhara Reddy*	Chairperson	Independent Director	2	2
Mr. Prabhakar Reddy Palakolanu@	Chairperson	Independent Director	3	3
Mrs. Khushboo Joshi**	Member	Independent Director	1	1
Mrs. Mounika Pammi#	Member	Independent Director	--	--

# CURA TECHNOLOGIES LIMITED

CIN: L84120TG1991PLC013479

Mrs. Priyanka Agarwal	Member	Independent Director	3	3
-----------------------	--------	----------------------	---	---

\*Resigned w.e.f. 07.01.2025

@Appointed as Chairperson w.e.f. 07.01.2025

\*\* Appointed w.e.f. 07.01.2025

# Appointed w.e.f. 30.05.2025

## POLICY FOR SELECTION OF DIRECTORS AND DETERMINING DIRECTORS' INDEPENDENCE:

### 1. Scope:

This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

### 2. Terms and References:

**2.1** "Director" means a director appointed to the Board of a Company.

**2.2** "Nomination and Remuneration Committee means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**2.3** "Independent Director" means a Director referred to in sub-Section (6) of Section 149 of the Companies Act, 2013 and Regulation 16 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

### 3. Policy:

#### 3.1 Qualifications and criteria

3.1.1 The Nomination and Remuneration Committee, and the Board, shall review on annual basis, appropriate skills, knowledge and experience required of the Board as a whole and its individual members. The objective is to have a Board with diverse background and experience that are relevant for the Company's operations.

3.1.2 In evaluating the suitability of individual Board member the NR Committee may take into account factors, such as:

- General understanding of the Company's business dynamics, global business and social

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

perspective;

- Educational and professional background
- Standing in the profession;
- Personal and professional ethics, integrity and values;
- Willingness to devote sufficient time and energy in carrying out their duties and responsibilities effectively.

3.1.3 The proposed appointee shall also fulfill the following requirements:

- shall possess a Director Identification Number;
- shall not be disqualified under the companies Act, 2013;
- shall Endeavour to attend all Board Meeting and Wherever he is appointed as a Committee Member, the Committee Meeting;
- shall abide by the code of Conduct established by the Company for Directors and senior Management personnel;
- shall disclose his concern or interest in any Company or companies or bodies corporate, firms, or other association of individuals including his shareholding at the first meeting of the Board in every financial year and thereafter whenever there is a change in the disclosures already made;
- Such other requirements as any prescribed, from time to time, under the Companies Act, 2013, Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other relevant laws.

3.1.4 The Nomination & Remuneration Committee shall evaluate each individual with the objective of having a group that best enables the success of the Company's business.

### **3.2 Criteria of Independence**

3.2.1 The Nomination & Remuneration Committee shall assess the independence of Directors at time of appointment/ re-appointment and the Board shall assess the same annually. The Board shall re-assess determinations of independence when any new interest or relationships are disclosed by a Director.

3.2.2 The criteria of independence shall be in accordance with the guidelines as laid down in Companies Act, 2013 and Regulation 16 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

An independent Director in relation to a Company, means a director other than a managing Director or a whole-time Director or a nominee Director

- i. who, in the opinion of the Board of directors, is a person of integrity and possesses

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

- relevant expertise and experience;
- ii. who is or was not a promoter of the listed entity or its holding, subsidiary or associate company or member of the promoter group of the listed entity;
  - iii. who is not related to promoters or directors in the listed entity, its holding, subsidiary or associate company;
  - iv. who, apart from receiving director's remuneration, has or had no material pecuniary relationship with the listed entity, its holding, subsidiary or associate company, or their promoters, or directors, during the three immediately preceding financial years or during the current financial year;
  - v. none of whose relatives—
    - a. is holding securities of or interest in the listed entity, its holding, subsidiary or associate company during the three immediately preceding financial years or during the current financial year of face value in excess of fifty lakh rupees or two percent of the paid-up capital of the listed entity, its holding, subsidiary or associate company, respectively, or such higher sum as may be specified;
    - b. is indebted to the listed entity, its holding, subsidiary or associate company or their promoters or directors, in excess of such amount as may be specified during the three immediately preceding financial years or during the current financial year;
    - c. has given a guarantee or provided any security in connection with the indebtedness of any third person to the listed entity, its holding, subsidiary or associate company or their promoters or directors, for such amount as may be specified during the three immediately preceding financial years or during the current financial year; or
    - d. has any other pecuniary transaction or relationship with the listed entity, its holding, subsidiary or associate company amounting to two percent or more of its gross turnover or total income: Provided that the pecuniary relationship or transaction with the listed entity, its holding, subsidiary or associate company or their promoters, or directors in relation to points (A) to (D) above shall not exceed two percent of its gross turnover or total income or fifty lakh rupees or such higher amount as may be specified from time to time, whichever is lower.
  - vi. who, neither himself /herself, nor whose relative(s) —
    - a. holds or has held the position of a key managerial personnel or is or has been an employee of the listed entity or its holding, subsidiary or associate company or any company belonging to the promoter group of the listed entity, in any of the three financial years immediately preceding the financial year in which he is proposed to be appointed:

Provided that in case of a relative, who is an employee other than key managerial personnel, the restriction under this clause shall not apply for his / her employment.

- b. is or has been an employee or proprietor or a partner, in any of the three financial years

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

immediately preceding the financial year in which he is proposed to be appointed, of

- (i) a firm of auditors or company secretaries in practice or cost auditors of the listed entity or its holding, subsidiary or associate company; or
  - (ii) any legal or a consulting firm that has or had any transaction with the listed entity, its holding, subsidiary or associate company amounting to ten per cent or more of the gross turnover of such firm;
  - c. holds together with his relatives two per cent or more of the total voting power of the listed entity; or
  - d. is a chief executive or director, by whatever name called, of any non-profit organisation that receives twenty-five per cent or more of its receipts or corpus from the listed entity, any of its promoters, directors or its holding, subsidiary or associate company or that holds two per cent or more of the total voting power of the listed entity;
  - e. is a material supplier, service provider or customer or a lessor or lessee of the listed entity;
- vii. who is not less than 21 years of age.
- viii. who is not a non-independent director of another company on the Board of which any non-independent director of the listed entity is an independent director:

3.2.3 The independent Director shall abide by the “code for independent Directors “as specified in Schedule IV to the companies Act, 2013.

### **3.3 Other Directorships/ Committee Memberships**

3.3.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board Performance Accordingly, members should voluntarily limit their Directorships in other listed public limited companies in such a way that it does not interfere with their role as Director of the Company. The NR Committee shall take into account the nature of, and the time involved in a Director service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.

3.3.2 A Director shall not serve as Director in more than 20 companies of which not more than 10 shall be public limited companies.

3.3.3 A Director shall not serve as an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed Company.

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

3.3.4 A Director shall not be a member in more than 10 committee or act as chairman of more than 5 committees across all companies in which he holds Directorships.

For the purpose of considering the limit of the committee, Audit committee and stakeholder's relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under Section 8 of the companies Act, 2013 shall be excluded.

### **Remuneration policy for Directors, key managerial personnel and other employees:**

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit.

The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities shouldered and individual performance.

### **Remuneration policy for Directors, key managerial personnel and other employees**

#### **1. Scope:**

1 This policy sets out the guiding principles for the Nomination and Remuneration committee for recommending to the Board the remuneration of the Directors, key managerial personnel and other employees of the Company.

#### **2. Terms and Reference:**

In this policy the following terms shall have the following meanings:

2.1 "Director" means a Director appointed to the Board of the Company.

2.2 "key managerial personnel" means

(i) The Chief Executive Officer or the managing Director or the manager;

(ii) The Company Secretary;

(iii) The Whole-time Director;

(iv) The Chief Financial Officer; and

(v) Such other office as may be prescribed under the companies Act, 2013

2.3 "Nomination and Remuneration committee" means the committee constituted by Board in accordance with the provisions of Section 178 of the companies Act, 2013, clause 49 of the Equity Listing Agreement and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements)

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

Regulations, 2015.

**3. Policy:**

**3.1 Remuneration to Executive Director and key managerial personnel**

**3.1.1 The Board on the recommendation of the Nomination and Remuneration (NR)**

The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the Company.

3.1.2 The remuneration structure to the Executive Director and key managerial personnel shall include the following components:

- (i) Basic pay
- (ii) Perquisites and Allowances
- (iii) Stock Options
- (iv) Commission (Applicable in case of Executive Directors)
- (v) Retrial benefits
- (vi) Annual performance Bonus

3.1.3 The Annual plan and Objectives for Executive committee shall be reviewed by the NR committee and Annual performance bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.

**3.2 Remuneration to Non – Executive Directors**

3.2.1 The Board, on the recommendation of the NR Committee, shall review and approve the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders as per the provisions of the Companies Act.

3.2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof. The Non- Executive Directors shall also be entitled to profit related commission in addition to the sitting fees.

**3.3. Remuneration to other employees**

3.3.1 Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

### **OTHER DIRECTORSHIPS/ COMMITTEE MEMBERSHIPS:**

- 4.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board performance. Accordingly, members should voluntarily limit their directorships in other listed public limited companies in such a way that it does not interfere with their role as director of the company. The NR Committee shall take into account the nature of and the time involved in a director's service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.
- 4.2 Director shall not serve as director in more than 20 companies of which not more than 10 shall be public limited companies.
- 4.3 Director shall not serve as an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed company.
- 4.4 Director shall not be a member in more than 10 committees or act as chairman of more than 5 committees across all companies in which he holds directorships.
- 4.5 For the purpose of considering the limit of the committee, Audit committee and stakeholder's relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under section 8 of the companies Act, 2013 shall be excluded.

### **(II). STAKEHOLDERS RELATIONSHIP COMMITTEE**

#### **A. BRIEF DESCRIPTION OF TERMS OF REFERENCE:**

The Committee's role includes:

- (i) Resolving the grievances of the security holders of the Company including complaints related to transfer/transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc;
- (ii) Review of measures taken for effective exercise of voting rights by shareholders;
- (iii) Review of adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent;

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

- (iv) Review of the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the company;
- (v) Such other matter as may be specified by the Board from time to time.
- (vi) Authority to review / investigate into any matter covered by Section 178 of the Companies Act, 2013 and matters specified in Part D of Schedule II of the Listing Regulations.

**B. COMPOSITION OF THE COMMITTEE, MEETINGS AND ATTENDANCE DURING THE YEAR:**

The Stakeholders Relationship Committee duly met one (01) time during the financial year from 1st April 2024 to 31st March 2025. The date on which the meeting was held is 13.02.2025.

Name	Designation	category	No. of Meetings held during the tenure	No. of meetings attended
Mr. K Rajasekhara Reddy*	Chairperson	Independent Director	--	--
Mr. Sangareddypeta Saikiran&	Member	Whole-time Director	1	1
Mr. Prabhakar Reddy Palakolanu@	Chairperson	Independent Director	1	1
Mrs. Khushboo Joshi**	Member	Independent Director	1	1
Mrs. Mounika Pammi#	Member	Independent Director	--	--

\*Resigned w.e.f. 07.01.2025

@Appointed as Chairperson w.e.f. 07.01.2025

\*\* Appointed w.e.f. 07.01.2025

# Appointed w.e.f. 30.05.2025

& ceases as member w.e.f 30.05.2025

NED (I): Non-Executive Independent director ED: Executive director

NED: Non-Executive director

## CURA TECHNOLOGIES LIMITED

CIN: L84120TG1991PLC013479

### C. DETAILS OF COMPLAINTS/REQUESTS RECEIVED, RESOLVED AND PENDING DURING THE YEAR 2024-25:

NUMBER OF COMPLAINTS	NUMBER
Number of complaints received from the investors comprising non-receipt of securities sent for transfer and transmission, complaints received from SEBI / Registrar of Companies / Bombay Stock Exchange / National Stock Exchange / SCORE and so on	NIL
Number of complaints resolved	NIL
Number of complaints not resolved to the satisfaction of the investors as on March 31, 2025.	NIL
Complaints pending as on March 31, 2025.	NIL
Number of Share transfers pending for approval, as on March 31, 2025.	NIL

#### 29. COMPOSITION OF CSR COMMITTEE AND CONTENTS OF CSR POLICY:

Since your Company does not have net worth of Rs. 500 Crores or more or turnover of Rs. 1000 Crores or more or a net profit of Rs. 5 Crores or more during the financial year, section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility is not applicable and hence the Company need not adopt any Corporate Social Responsibility Policy.

#### 30. VIGIL MECHANISM/ WHISTLE BLOWER POLICY:

The Company has formulated a Vigil Mechanism / Whistle Blower Policy pursuant to Reg. 22 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 and Section 177(10) of the Companies Act 2013, enabling stakeholders to report any concern of unethical behaviour, suspected fraud or violation.

The said policy inter-alia provides safeguard against victimization of the Whistle Blower. Stakeholders including directors and employees have access to the Vice Chairman and Managing Director and Chairperson of the Audit Committee.

During the year under review, no stakeholder was denied access to the Chairperson of the Audit Committee.

#### 31. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:

There are no significant and material orders passed by the regulators / courts that would impact the going concern status of the Company and its future operations.

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**32. STATUTORY AUDITORS AND STATUTORY AUDITORS REPORT:**

**Statutory Auditors:**

The members of the company approved the appointment of M/s. Pundarikashyam and Associates, Chartered Accountants as Statutory Auditors of the company for the term of five years from 01.04.2024 to 31.03.2029 upto conclusion of 38th Annual General meeting to be held for financial year 2028-29.

The Auditors' Report for fiscal 2025 does not contain any qualification, reservation or adverse remark. The Auditors' Report is enclosed with the financial statements in this Annual Report. The Company has received audit report with unmodified opinion for both Standalone and Consolidated audited financial results of the Company for the Financial Year ended March 31, 2025 from the statutory auditors of the Company. The Auditors have confirmed that they have subjected themselves to the peer review process of Institute of Chartered Accountants of India (ICAI) and hold valid certificate issued by the Peer Review Board of the ICAI.

**33. INTERNAL AUDITOR:**

Pursuant to provisions of Section 138 read with Rule 13 of the Companies (Accounts) Rules, 2014 and Section 179 read with Rule 8(4) of the Companies (Meetings of Board and its Powers) Rules, 2014; during the year under review the Internal Audit of the functions and activities of the Company was undertaken by the Internal Auditor of the Company on quarterly basis by M/s. Pavan Reddy & Associates, Chartered Accountants Internal Auditors of the Company.

Deviations are reviewed periodically and due compliance ensured. Summary of Significant Audit Observations along with recommendations and its implementations are reviewed by the Audit Committee and concerns, if any, are reported to Board. There were no adverse remarks or qualification on accounts of the Company from the Internal Auditor.

**34. SECRETARIAL AUDITOR:**

In terms of section 204 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, based upon the recommendations of the Audit Committee, the Board of Directors had appointed M/s. Manoj Parakh & Associates, Practicing Company Secretaries as the Secretarial Auditor of the Company, for conducting the Secretarial Audit for financial year ended March 31, 2025.

The Secretarial Audit was carried out by M/s. Manoj Parakh & Associates, Company Secretaries for the financial year ended March 31, 2025. The Report given by the Secretarial Auditor is annexed herewith as **Annexure- I** and forms integral part of this Report.

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

The Secretarial Audit Report does not contain any qualification, reservation or adverse remark.

M/s. Aakanksha Dubey & Co., Practicing Company Secretaries, was appointed as Secretarial auditors for FY 2025-26 in the Board meeting held on 30.05.2025.

### **35. SECRETARIAL STANDARDS:**

Pursuant to the provisions of Section 118 of the Companies Act, 2013, the Company has complied with the applicable provisions of the Secretarial Standards issued by the Institute of Company Secretaries of India and notified by Ministry of Corporate Affairs.

### **36. DECALARATION BY THE COMPANY:**

The Company has issued a certificate to its Directors, confirming that it has not made any default under Section 164(2) of the Act, as on March 31, 2025.

### **37. POLICY ON DIRECTOR'S APPOINTMENT AND REMUNERATION:**

In adherence to the provisions of Section 134(3)(e) and 178(1) & (3) of the Companies Act, 2013, the Board of Directors upon recommendation of the Nomination and Remuneration Committee approved a policy on Director's appointment and remuneration, including, criteria for determining qualifications, positive attributes, independence of a Director and other matters.

### **38. ANNUAL RETURN:**

As required pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014, an annual return is uploaded on website of the Company [www.curatechnologies.in](http://www.curatechnologies.in)

### **39. DISCLOSURE ABOUT COST AUDIT:**

Maintenance of cost records and requirement of cost audit as prescribed under the provisions of Section 148(1) of the Act, are not applicable for the business activities carried out by the Company.

### **40. MANAGEMENT DISCUSSION AND ANALYSIS REPORT:**

Management discussion and analysis report for the year under review as stipulated under Regulation 34 (e) read with schedule V, Part B of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 with the stock exchange in India is annexed herewith as **Annexure- III** to this report.

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**41. FAMILIARISATION PROGRAMMES:**

The Company familiarizes its Independent Directors on their appointment as such on the Board with the Company, their roles, rights, responsibilities in the Company, nature of the industry in which the Company operates, etc. through familiarization programme. The Company also conducts orientation programme upon induction of new Directors, as well as other initiatives to update the Directors on a continuing basis. The familiarization programme for Independent Directors is disclosed on the Company's website [www.curatechnologies.in](http://www.curatechnologies.in).

**42. CORPORATE GOVERNANCE AND SHAREHOLDERS INFORMATION:**

Since the paid-up capital of the Company is less than Rs. 10 Crores and Net worth of the Company is less than Rs. 25 Crores, Corporate Governance is Not Applicable.

**43. NON-EXECUTIVE DIRECTORS' COMPENSATION AND DISCLOSURES:**

None of the Independent / Non-Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgment of the Board may affect the independence of the Directors.

**44. OTHER ACTIVITIES:**

**Registered Office:**

During the year under review, the Board of Directors in its meeting held on 06.04.2024 has changed its registered office from Sy No.68, Flat No.204, Hema Durga Plaza, Allwyn Colony, Miyapur, Hyderabad-500049, Telangana TO Unit No 604 B, Jain Saduguru Capital Park, Beside Image Gardens, Madhapur, Hyderabad – 500081.

**45. CORPORATE INSOLVENCY RESOLUTION PROCESS INITIATED UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (IBC):**

During the year under review, there were no applications made or proceedings pending in the name of the Company under Insolvency and Bankruptcy Code, 2016.

**46. CODE OF CONDUCT FOR THE PREVENTION OF INSIDER TRADING:**

The Board of Directors has adopted the Insider Trading Policy in accordance with the requirements of the SEBI (Prohibition of Insider Trading) Regulation, 2018. The Insider Trading Policy of the Company lays down guidelines and procedures to be followed, and disclosures to

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

be made while dealing with shares of the Company, as well as the consequences of violation. The policy has been formulated to regulate, monitor and ensure reporting of deals by employees and to maintain the highest ethical standards of dealing in Company securities.

The Insider Trading Policy of the Company covering code of practices and procedures for fair disclosure of unpublished price sensitive information and code of conduct for the prevention of insider trading is available on our website [www.curatechnologies.in](http://www.curatechnologies.in).

### **47. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN ATWORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:**

The Company has zero tolerance for sexual harassment at workplace and has adopted a Policy on Prevention, Prohibition, and Redressal of Sexual Harassment at workplace.

This is in line with provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 ('POSH Act') and the Rules made thereunder. With the objective of providing a safe working environment, all employees (permanent, contractual, temporary, trainees) are covered under this Policy. The policy is available on the website at [www.curatechnologies.in](http://www.curatechnologies.in)

As per the requirement of the POSH Act and Rules made thereunder, the Company has constituted an Internal Committee at all its locations known as the Prevention of Sexual Harassment (POSH) Committees, to inquire and redress complaints received regarding sexual harassment. During the year under review, there were no Complaints pertaining to sexual harassment.

All employees are covered under this policy. During the year 2024-25, there were no complaints received by the Committee.

### **48. DETAILS OF DIFFERENCE BETWEEN VALUATION AMOUNT ON ONE TIME SETTLEMENT AND VALUATION WHILE AVAILING LOAN FROM BANKS AND FINANCIAL INSTITUTIONS:**

During the year under review, there has been no one-time settlement of loans taken from banks and financial institutions.

### **49. FAILURE TO IMPLEMENT CORPORATE ACTIONS:**

During the year under review, no corporate actions were done by the Company which were failed to be implemented.

### **50. INDUSTRY BASED DISCLOSURES AS MANDATED BY THE RESPECTIVE LAWS GOVERNING THE COMPANY:**

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

The Company is not a NBFC, Housing Companies etc., and hence Industry based disclosures is not required.

**51. POLICIES:**

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the formulation of certain policies for all listed companies. All the policies are available on our website i.e. [www.curatechnologies.in](http://www.curatechnologies.in).

**52. COMPLIANCE WITH THE MATERNAL BENEFIT ACT,1961**

The Company has complied with the provisions of the Maternal Benefit Act, amendments and rules framed thereunder. All eligible women employees are provided with maternal benefits as prescribed under Act,1961, including paid maternity leave, nursing breaks and protection from dismissal during maternity leave.

**53. EVENT BASED DISCLOSURES:**

During the year under review, the Company has not taken up any of the following activities except as mentioned:

- a) Issue of sweat equity share: NA
- b) Issue of shares with differential rights: NA
- c) Issue of shares under employee's stock option scheme: NA
- d) Disclosure on purchase by Company or giving of loans by it for purchase of its shares: NA
- e) Buyback shares: NA
- f) Disclosure about revision: NA
- g) Preferential Allotment of Shares: Yes.

Allotment of 7,50,000 equity shares of Rs. 10/- each at an issue price of Rs. 10/- to Strategic Financial Investor on cash basis as per the Resolution Plan.

- h) Issue of equity shares with differential rights as to dividend, voting: NA

**54. APPRECIATION & ACKNOWLEDGEMENTS:**

Your Directors place on record their appreciation for the overwhelming co-operation and assistance received from the investors, customers, business associates, bankers, vendors, as

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

well as regulatory and governmental authorities. Your Directors also thanks the employees at all levels, who through their dedication, co-operation, support and smart work have enabled the company to achieve a moderate growth and is determined to poise a rapid and remarkable growth in the year to come.

Your Directors also wish to place on record their appreciation of business constituents, banks and other financial institutions and shareholders of the Company, SEBI, BSE, NSE, NSDL, CDSL, Bankers etc. for their continued support for the growth of the Company.

**For and on behalf of the Board  
For Cura Technologies Limited**

**Place: Hyderabad**

**Date: 04.09.2025**

**Sangareddypeta Sai Kiran**

**Whole time director & CFO**

**(DIN: 09741325)**

**Sanjana Lagumavarapu**

**Managing Director**

**(DIN: 09440632 )**

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**ANNEXURE I**

**FORM MR-3 SECRETARIAL AUDIT REPORT**

(Pursuant to section 204(1) of the Companies Act, 2013 and  
Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules,  
2014

**FOR THE FINANCIAL YEAR ENDED 31<sup>ST</sup> MARCH, 2025**

**To,**  
**The Members of**  
**Cura Technologies Limited**

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Cura Technologies Limited (hereinafter called "the Company"). Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's Books, Papers, Minutes Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the financial year commencing from 1<sup>st</sup> April, 2024 and ended 31<sup>st</sup> March, 2025 complied with the statutory provisions listed hereunder and also that the Company has proper Board- processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made herein after:

- i. We have examined the books, papers, minutes book, forms and returns filed and other records maintained by the Company for the financial year ended on 31<sup>st</sup> of March, 2025 according to the provisions of:
  - (i) The Companies Act, 2013 (the Act) and the rules made there under;
  - (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;
  - (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
  - (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment (FDI), Overseas Direct Investment and External Commercial Borrowings;

## CURA TECHNOLOGIES LIMITED

CIN: L84120TG1991PLC013479

- ii. Compliance status in respect of the provisions of the following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI ACT') is furnished hereunder for the financial year 2024- 2025 :-
1. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; **to the extent applicable**
  2. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Amended Regulations 2018 Insider Trading Regulations; **The Company has framed code of conduct for regulating & reporting trading by insiders and for fair disclosure and displayed the same on the Company's website i.e. [www.curatechnologies.in](http://www.curatechnologies.in).**
  3. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
  4. The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; **Not Applicable as the Company has not issued any Employee Stock Options during the year under review.**
  5. The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; **Not Applicable as the Company has not issued and listed any debt or non-convertible securities during the year under review.**
  6. The Securities and Exchange Board of India (Registrars to an issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client; **Not Applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the year under review. However, the Company has Venture Capital & Corporate Investments Private Limited as its Share Transfer Agent.**
  7. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; **Not Applicable as the Company has not delisted/ proposed to delist its equity shares during the year under review.**
  8. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **Not Applicable as the Company has not bought back/ proposed to buy-back any of its securities during the year under review.**
  9. Other applicable laws include the following:
    - a. Information Technology Act, 2000 as amended from time to time.
    - b. Income Tax Act, 1961
    - c. Minimum Wages Act, 1948
    - d. Goods and Services Tax Act, 2016 and Rules made there under
    - e. The Payment of Gratuity Act, 1972

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by the Institute of Company Secretaries of India.
- (ii) The Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015 were complied with to the extent applicable.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above subject to the following observations:

- (i) External Commercial Borrowings were not attracted to the Company under the financial year under report.
- (ii) Foreign Direct Investment (FDI) was not attracted to the Company under the financial year under report;
- (iii) Overseas Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary abroad was not attracted to the Company under the financial year under report.
- (iv) As per the information and explanations provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we report that the Company has not made any GDRs/ADRs or any Commercial Instrument under the financial year under report.

We further report that:

- Mr. Sangareddypeta Saikiran is the Chief Financial Officer of the Company. Mr. Nitesh Kumar Sharma resigned as Company Secretary and Compliance Officer w.e.f. 18.09.2024 and Mrs. Sharvari Swapnil Shinde was appointed as Company Secretary and Compliance Officer w.e.f. 18.09.2024.
- The Company has appointed M/s. Pavan Reddy & Associates., as internal auditor for FY 2024-25.
- The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors after the implementation of the Resolution Plan. There was change in the composition of the Board of Directors during the period under review and the same was carried out in compliance with the provisions of the Act.
- Adequate notice of Board meeting is given to all the directors along with agenda at least seven days in advance after the appointment of new directors as per the Resolution Plan and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and meaningful participation at the meeting.

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

- As per the minutes of the meeting duly recorded and signed by the Chairman of the meeting, the decisions of the Board were unanimous and no dissenting views have been recorded.
  
- We, further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
  
- The Compliance by the Company of applicable financial Laws like Direct and Indirect tax Laws has not been reviewed thoroughly in this audit since the same has been subject to review by statutory financial Audit and other designated professionals.
  
- We further report that during the year under report, the Company has not undertaken event/action having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards etc except the following:
  - a) The Board of Directors in its meeting held on 06.04.2024 has changed its registered office from Sy No.68, Flat No.204, Hema Durga Plaza, Allwyn Colony, Miyapur, Hyderabad-500049, Telangana TO Unit No 604 B, Jain Saduguru Capital Park, Beside Image Gardens, Madhapur, Hyderabad – 500081.
  
  - b) Allotment of 72,00,000 equity shares of Rs. 10/- each on 13.02.2025 to the shareholders of Catalog IT Solutions Private Limited (Transferor Company) pursuant to the approve of the Scheme of Arrangement between M/s. Catalog IT Solutions Private Limited (Transferor Company) and M/s. Cura Technologies Limited (Transferee Company) as per the Resolution Plan approved by Hon'ble NCLT, Hyderabad Bench vide Orders dated 14.09.2023.
  
  - c) Allotment of 7,50,000 equity shares of Rs. 10/- each on 21.06.2025 to the strategic investors as per the Resolution Plan approved by Hon'ble NCLT, Hyderabad Bench vide Orders dated 14.09.2023.

For Manoj Parakh & Associates

Manoj Parakh

Proprietor

M.NO. F8572; C. P. No: 8957

UDIN: F008572G001170480

Peer Review Cer. No.: 3439/2023

Place: Visakhapatnam

Date : 04.09.2025

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**Annexure A**

To  
The Members of  
Cura Technologies Limited

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have relied on the reports given by the concerned professionals in verifying the correctness and appropriateness of financial records and books of accounts of the Company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The secretarial Audit report is neither an assurance as to future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For Manoj Parakh & Associates

Manoj Parakh  
Proprietor

M.NO. F8572; C. P. No: 8957

UDIN: F008572G001170480

Peer Review Cer. No.: 3439/2023

Place: Visakhapatnam

Date : 04.09.2025

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**ANNEXURE II**

**Form No. AOC-2**

*(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)*

Form for disclosure of particulars of contracts/arrangements entered into by the Company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto

- 1. Details of contracts or arrangements or transactions not at arm's length basis:** Not Applicable as all the Related Party Transactions have been entered into at an arm's length basis.
- 2. Details of material contracts or arrangement or transactions at arm's length basis:** nil

**FOR AND ON BEHALF OF THE BOARD  
FOR CURA TECHNOLOGIES LIMITED**

**PLACE: HYDERABAD**

**DATE: 04.09.2025**

**SANGAREDDYPETA SAI KIRAN**

**WHOLE TIME DIRECTOR & CFO  
(DIN:09741325)**

**SANJANA LAGUMAVARAPU**

**MANAGING DIRECTOR  
(DIN: 09440632 )**

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**Annexure III**

**MANAGEMENT DISCUSSION AND ANALYSIS REPORT**

**INDUSTRY STRUCTURE AND DEVELOPMENTS:**

The IT industry is structured into services, software products, engineering R&D, and digital platforms. India leads globally in IT exports. Rapid adoption of AI, cloud, and cybersecurity is transforming operations. Government initiatives like Digital India and Startup India are fueling innovation and infrastructure. The rise of tech startups and global capability centers is reshaping the landscape. Overall, the industry is poised for sustained growth and deeper global integration.

The IT industry is experiencing robust growth, with India's IT sector projected to reach USD \$350 billion by 2026 and contribute 10% to the GDP, driven by strong demand for AI, cloud, and cyber security services. Key developments include substantial government investment in AI infrastructure and talent development through initiatives like the India AI mission and a proposed Deep Tech Fund. The industry is also expanding its global footprint, focusing on international investment and the establishment of Global Capability Centres in tier-2 cities, while the recent Union Budget emphasizes tax reforms and local production of electronics to boost the sector. The industry is well-diversified across various verticals like BFSI (Banking, Financial Services, and Insurance), telecom, and retail, with a growing demand from emerging sectors.

**OPPORTUNITIES AND THREATS:**

Opportunities in the IT industry are abundant, driven by rapid advancements in technology, with high-demand roles including AI/ML Engineering, Cloud Engineering, Cyber security, Data Science, and Software Development. Other growing fields include Web Development, Dev Ops, Mobile Development, and roles in IT Management and Project Management. These diverse roles span various sectors, from tech companies to government agencies, providing lucrative and rewarding career paths. The Company just came out from CIRP proceedings and is actively pursuing various business options as a part of revival of the business operations. Further the company is exploring new business opportunities and is in the process of Identifying the Company/ies for acquisition or take control to achieve inorganic growth and also option of funding to meet the same.

The primary threats in the IT industry are sophisticated cyberattacks, including ransomware, phishing, malware, and Distributed Denial-of-Service (DDoS) attacks, often facilitated by poor cybersecurity practices and human error. Other major threats involve exploiting software vulnerabilities, supply chain risks, insider threats, and the growing threat of AI-powered

## **CURA TECHNOLOGIES LIMITED**

**CIN: L84120TG1991PLC013479**

attacks. These attacks aim to steal data, disrupt systems, and cause significant financial and reputational damage.

### **SEGMENT WISE PERFORMANCE:**

Since, the Company operates its business under one segment only, the report on segment wise performance is not applicable. In the financial year 2024-25, the Company could take all necessary steps to comply with Orders of Hon'ble NCLT like complete all the legal formalities including constitution of the Board, committees and appointment of KMPs, regularization of all the filings with the Exchanges in terms of SEBI (LODR) Regulations, 2015 and Companies Act, 2013 by duly complying the approved plan as per the Order. Now the management is rigorously working on the development of the business and expecting reasonable results in the near future.

### **OUTLOOK:**

The outlook for the IT industry is cautiously optimistic, with strong growth projected for India's IT exports and overall IT spending, driven by the US market recovery and generative AI. However, a weakening European market and global economic headwinds present challenges. The sector is poised for increased growth in FY26, with a shift toward mid-tier firms outpacing larger competitors and a greater focus on software, data centers, and private cloud solutions. Presently the outlook is very promising.

### **RISK & CONCERN:**

The new management of the Company shall review the existing risk management policy and lay down defined risk management mechanism covering the risk mapping and trend analysis, risk exposure, potential impact and risk mitigation process. Management will take steps to identify and evaluate, manage and monitor various risk.

### **INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:**

Pursuant to the taking over of the operations of the Company by the new management, the Company would comply with Internal Financial Controls, commensurate with the size, scale and complexity of the Company's operations.

### **DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE:**

The Company has been working for the last one and a half years for completion of the listing of equity shares post implementation of the approved plan, now reached to a meaningful phase wherein by allotment of shares to the respective shareholders as per the plan, reduction of capital relating to the erstwhile public shareholders, allotments and listing of shares relating to strategic investors and to the shareholder of the target company as per the merger and as per approved plan could be completed.

The Money raised through allotment from the Resolution applicant and Strategic Investors was properly

## CURA TECHNOLOGIES LIMITED

CIN: L84120TG1991PLC013479

spent for the discharge of liabilities as per the approved Resolution Plan, payment of Fees/dues to the Exchanges/ Statutory Organizations.

The management would be able to contribute more on building the business both in organic and inorganic form. The hard work put in by the management in the last one and a half year with respect to implementation of Orders of Hon'ble NCLT are expected to yield results in the FY 2025-26.

### MATERIAL DEVELOPMENTS IN HUMAN RESOURCES/INDUSTRIAL RELATIONS FRONT, INCLUDING NUMBER OF PEOPLE EMPLOYED:

The company is in process of recruiting experienced personnel at senior level apart from strengthening other departments with competent people as a part of revival of the Company in terms of Orders of Hon'ble NCLT.

### RISK MANAGEMENT FRAMEWORK:

Post revival from IBC, the Company has placed an enterprise risk management framework for identifying risks and opportunities that may have a bearing on the organization's objectives, assessing them in terms of likelihood and magnitude of impact and determining a response strategy.

### DETAILS OF SIGNIFICANT CHANGES (I.E. CHANGE OF 25% OR MORE ASCOMPARED TO THE IMMEDIATELY PREVIOUS FINANCIAL YEAR) IN KEYFINANCIAL RATIOS, ALONG WITH DETAILED EXPLANATIONS THEREFOR, INCLUDING:

Particulars	Formulae	As at March 31, 2025	As at March 31, 2024	% Change	Reason for Variance
Debtors Turnover Ratio	Net Credit Sales/Average Trade Receivables	-	-	-	No trade receivables or credit sales in either year.
Inventory Turnover Ratio	Cost of Goods sold/Average Inventory	-	-	-	No inventory held or consumed in either year.
Interest Coverage Ratio	EBIT / Interest Expense	(13,117.44)	-	-	EBIT was negative in FY 2025 due to operating losses; no interest expense in FY 2024.
Current Ratio	Current Assets/Current Liabilities	0.17	-	Not Comparable	Surge in current liabilities (₹7.28 Cr) in FY 2025 vs. nil in FY 2024.
Debt Equity Ratio	Total liabilities/Shareholder's Equity	1.65	-	Not Comparable	Introduction of ₹11.75 Cr in liabilities and

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

					expansion of equity base in FY 2025.
Operating Profit Margin (%)	Operating Profit / Revenue	-	-	-	Revenue not reported; margin calculation not feasible.
Net Profit Margin (%)	Net Profit / Revenue	-	-	-	Revenue not reported; margin calculation not feasible.

**Details of any change in Return on Net Worth as compared to the immediately previous financial year along with a detailed explanation thereof.**

**DISCLOSURE OF ACCOUNTING TREATMENT:**

The Company has not carried out any treatment different from that prescribed in Accounting Standards.

**CAUTIONARY STATEMENTS:**

Certain statements in the Management Discussion and Analysis describing the Company's objectives, predictions may be "forward-looking statements" within the meaning of applicable laws and regulations. Actual results may vary significantly from the forward-looking statements contained in this document due to various risks and uncertainties. These risks and uncertainties include the effect of economic and political conditions in India, volatility in interest rates, new regulations and Government policies that may impact the Company's business as well as its ability to implement the strategy. The Company does not undertake to update these statements.

**FOR AND ON BEHALF OF THE BOARD**  
**FOR CURA TECHNOLOGIES LIMITED**

**PLACE: HYDERABAD**  
**DATE: 04.09.2025**

**SANGAREDDYPETA SAI KIRAN**  
**WHOLE TIME DIRECTOR & CFO**  
**(DIN:09741325)**

**SANJANA LAGUMAVARAPU**  
**MANAGING DIRECTOR**  
**(DIN: 09440632 )**

**CURA TECHNOLOGIES LIMITED**  
**CIN: L84120TG1991PLC013479**

**ANNEXURE – IV(A)**

**REMUNERATION RATIO OF THE DIRECTORS / KEY MANAGERIAL PERSONNEL (KMP) / EMPLOYEES FOR THE FINANCIAL YEAR 2024-25.**

**A. Statement of Disclosure under Section 197 (12) read with Rule 5(1) of The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:**

1. Ratio of remuneration of each Executive Director to the median remuneration of the Employees of the Company and percentage increase in remuneration of Key Managerial Personnel (KMP) and other Executive Directors during the Financial Year 2024-25:

**The ratio of remuneration to each director to the median remuneration of the employees of the Company for the financial year.**

(Amt in Rs.)

	Director	Total Remuneration	Ratio to median remuneration
1	NIL		

**The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year.**

(Amt in Rs.)

Name	Designation	Remuneration		Increase/ (Decrease) %
		FY 2024-25	FY 2023-24	
Mr. Nitesh Kumar Sharma	Company Secretary and Compliance Officer	1,10,000	1,10,000	
Mrs. Sharvari Swapnil Shinde	Company Secretary and Compliance Officer	2,70,000	--	

## CURA TECHNOLOGIES LIMITED

CIN: L84120TG1991PLC013479

The percentage increase in the median remuneration of employees in the financial year

Particulars	Increase/(Decrease)%
Median Remuneration of all the employees per annum*	NIL

Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile

increase in the managerial remuneration and justification thereof and details if there are any exceptional circumstances for increase in the managerial remuneration

Particulars	Increase/(Decrease) %
Average percentage increase in the remuneration of all Employees* (Other than Key Managerial Personnel)	NIL
Average Percentage increase in the Remuneration of Key Managerial Personnel	Nil
*Employees who have served for whole of the respective financial years have been considered.	

### 6. Affirmation that the remuneration is as per the remuneration policy of the Company.

The Company is in compliance with its remuneration policy.

**Annexure IV (b).**

**B. Information as per Rule 5(2) of Chapter XIII of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014**

1. Top 10 employees of the Company based on Remuneration drawn for FY 2024-25

S N o	Name of the Employee	Designa tion of the employ ee	Remu nerati on receiv ed	Natur e of emplo yment wheth er contra ctual or other wise	Qualifi cation and experie nce of the emplo yee	Date of comm ence of emplo yment	The age of the employ ee	The last employ ment held by such employ ee before joining the Compan y	The percentage of equity shares held by the employee in the Company within the meaning of clause (iii) of sub rule (2) of Rule 5 of the Companies (Appointm ent and Remunerat ion of Managerial Personnel) Rules, 2014	Whether any such employee is a relative of any director or manager of the Company and if so, name of such director or manager
1	Mrs. Sharvari Swapnil Shinde	Compan y Secretar y and Complia nce Officer	Rs. 45000 per mont h	Contr actual	CS	18.09. 2024	38 years	NA	Nil	NA

## **INDEPENDENT AUDITOR'S REPORT**

### **TO THE MEMBERS OF CURA TECHNOLOGIES LIMITED**

#### **Opinion**

We have audited the accompanying IndAS Financial Statements of **CURA TECHNOLOGIES LIMITED** (the "Company"), which comprise the Balance Sheet as at March 31, 2025, the Statement of Profit and Loss (including the statement of Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended on that date and a summary of significant accounting policies and other explanatory information. (hereinafter referred to as the "financial statements").

In our opinion and to the best of our information and according to the explanations given to us, except for the possible effects of the matter described in the Basis for Opinion paragraph, the aforesaid financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025 and its financial performance including other comprehensive income, changes in equity and its cash flows for the year ended on that date.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Emphasis of Matter**

Attention is invited to following notes of the financial statements:

We draw attention to Note [14] of the financial statements, which describes that the accounting software used by the Company does not have an enabled audit trail (edit log) feature to automatically log changes made to accounting data and that the Company has also not maintained daily backups of its accounting data during the year. These matters have been disclosed in the financial statements by the management. Our opinion is not modified in respect of these matters.

We also draw your attention to Note [15] of the accompanying financial statements, which describes that M/s. Catalog IT Solutions Private Limited (the 'Transferor Company') has been amalgamated with M/s. Cura Technologies Limited with effect from 13th February, 2025 pursuant to the Scheme of Amalgamation/Merger (the 'Scheme') between the Company and Catalog IT Services Private Limited, as approved by the Hon'ble National Company Law Tribunal, Hyderabad Bench vide Orders dated 14.09.2023. The Company has given accounting effect to the business combination in accordance with the Scheme and the accounting principles prescribed in Ind AS 103, Business Combinations. Our opinion is not modified in respect of this matter.

### **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined that there are no key audit matters to communicate in our report.

### **Information other than the Financial Statements and Auditor's Report thereon**

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance and conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

### **Management's Responsibility for the financial statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the act") with respect to the preparation of these financial statements that give a

true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Management either Intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditors' Responsibility for the Audit of Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Standards on Auditing, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- ❖ Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ❖ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also

responsible for explaining our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.

- ❖ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- ❖ Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- ❖ Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- ❖ Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.
- ❖ We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
- ❖ We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
- ❖ From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse

consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Act, we give in the '**Annexure A**', a statement on the matters specified in the paragraph 3 and 4 of the order.
  
2. As required by Section 143 (3) of the Act, we report that
  - a) We have sought and obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit. The Management assures of the matching balances in counterparty's books.
  - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c) The Balance Sheet, the Statement of Profit and Loss, including Other Comprehensive Income, Statement of Changes in Equity and the Cash Flow Statement dealt with by this Report are in agreement with the relevant books of accounts.
  - d) In our opinion, the aforesaid financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
  - e) On the basis of the written representations received from the directors as on 31<sup>st</sup> March, 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.
  - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in '**Annexure B**'.
  - g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us.
    - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements.
    - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
    - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
    - iv. a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of

funds) by the Company to or in any other person or entity, including foreign entity (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

- v. The Company has neither paid nor declared any dividend during the year. Therefore, compliance of Section 123 of the Act is not required.

**For PUNDARIKASHYAM AND ASSOCIATES**

Chartered Accountants

Firm Reg. No: 011330S

**B. SURYA PRAKASA RAO**

Partner

Membership No: 205125

UDIN: 25205125BMHZOM1557

Place: Hyderabad

Date: 30<sup>th</sup> May, 2025

## **ANNEXURE 'A' TO THE INDEPENDENT AUDITORS' REPORT**

Annexure referred to in Independent Auditors Report to the Members of Cura Technologies Limited on the Financial Statements for the year ended 31<sup>st</sup> March 2025.

According to information and explanations given to us, we report that:

1. In respect of the Company's Property, Plant and Equipment and Intangible Assets:
  - a. The records maintained by the company display the complete particulars on the details, quantity and situation of tangible and intangible assets.
  - b. The property, plant and equipment were physically verified during the year by the management in accordance with a regular programme of verification which, in our opinion, provides for physical verification of all the property, plant and equipment at reasonable intervals. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
  - c. According to the information and explanations given by the management and audit procedures performed by us, the title deeds of immovable properties included in property, plant and equipment are held in the name of the Company.
  - d. The Company has not revalued its Property, Plant & Equipment or intangible assets or both during the year.
  - e. There are no proceedings initiated or pending against the Company for holding any Benami property under the prohibition of Benami property Transactions Act, 1988 and the rules made under.
2.
  - a. As the company is into providing software services and as there are no major activities of the Company taken place during the year, there is no inventory during the year. Therefore, Paragraph 3 (ii) (b) of the order is not applicable to the Company.
  - b. The Company has not been sanctioned working capital limits in excess of ₹ 5 crore, in aggregate, at any points of time during the year, from banks or financial institutions on the basis of security of current assets and hence reporting under clause 3(ii)(b) of the Order is not applicable.
3. The Company has not granted any loans, secured or unsecured, to companies, firms, and Limited Liability partnerships or other parties covered in the register maintained under section 189 of the Companies Act, 2013. Therefore, the provisions of Clause 3(iii), (iii)(a), (iii)(b) and (iii)(c) of the said order are not applicable to the company.
4. In our opinion and according to the information and explanation provided to us, there are no loans, investments, guarantees and securities, provided during the year and hence, the provisions of section 185 and 186 of the Companies Act, 2013 are not applicable.

5. The Company has not accepted any deposits from the public covered under Section 73 to 76 of the Companies Act, 2013 and rules framed there under to the extent notified.
6. The maintenance of cost records has not been specified by the Central Government under section 148(1) of the Companies Act, 2013 for business activities carried out by the Company. Thus, reporting under clause 3(vi) of the order is not applicable to the company.
7.
  - (a) According to the information and explanations given to us and based on the records of the company examined by us, the company is regular in depositing the Undisputed statutory dues, including Provident Fund, Employees' State Insurance, Income-tax, Custom Duty, Goods and Services Tax, as applicable, with the appropriate authorities;
  - (b) There were no Undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Professional Tax, TDS, Service Tax, and Value Added Tax dues in arrears as at 31<sup>st</sup> March 2025 for a period of more than 6 months from the date they became payable.
  - (c) According to the information and explanations given to us, there are no dues of Wealth tax, duty of customs, duty of excise which have not been deposited on account of any dispute.
8. The Company has not surrendered or disclosed any transaction, previously unrecorded in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year. Accordingly, the requirement to report under Clause (viii) of paragraph 3 is not applicable.
9. The Company has taken not taken any term loans from Banks and Financial institutions.
10.
  - a. The Company has not raised any moneys by way of initial public offer, further public offer (including debt instruments) and no term loans were availed during the year.
  - b. The Company has made preferential allotment or private placement of shares during the year and the requirements of Section 42 and Section 62 of the Companies Act 2013 have been complied with and the funds raised have been used for the purposes for which the funds were raised.
11.
  - a. No fraud by the Company and no material fraud on the Company has been noticed or reported during the year.
  - b. No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to the date of this report.
  - c. As represented to us by the management, there are no whistle blower complaints received by the Company during the year.
12. The Company is not a Nidhi Co. and therefore clause 3(xii) of the Order is not applicable to the Company and we do not comment upon this provision.

13. In our opinion, all the Related Party Transactions entered into by the Company during the year are in compliance with the provisions Sec. 188 & 177 of the Act and the details thereof have been disclosed in the Financial Statements as required by the accounting standards and the Act.
14. The Company based on the size and nature of business, is required to maintain an Internal Audit system as per the Companies Act, 2013. And the same has been complied with by the Company.
15. The Company has not entered into any non-cash transactions with directors / persons connected with him as stipulated U/s. 192 of the Act. Clause 3(xv) of the Order is therefore not applicable to the Company.
16.
  - a. The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a), (b) and (c) of the Order is not applicable.
  - b. The Company has not conducted any Non-banking Financial or Housing Finance activities during the year.
  - c. The Company is not a core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and accordingly reporting under clause 3(xvi)(d) of the order is not applicable.
17. The Company had incurred cash losses of Rs. 66.23 Lakhs in the current Financial Year and there are cash losses of Rs.94.08 Lakhs in the immediately preceding financial year.
18. There had been no resignation of Statutory Auditors during the financial year.
19. On the basis of financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the Audit Report indicating that the company is not capable of meeting its liabilities existing as at the date of Balance Sheet as and when they fall due within period of one year from the Balance Sheet Date. We however, state that our reporting is based on the facts upto the date of the Audit Report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance Sheet date, will get discharged by the Company as and when they fall due.
20. According to the information and explanation given to us and based on the verification of the records of the company, we report that
  - a. In respect of other than ongoing projects, there are no unspent amounts that are required to be transferred to a fund specified in Schedule VII of the Act, in compliance with second proviso to sub section 5 of section 135 of the Act.
  - b. There are no unspent amounts in respect of ongoing projects, that are required to be transferred to a special account in compliance of provision of sub section (6) of section 135 of the Act.

21. The Company is a Standalone Entity and hence, the reporting under Paragraph 3(xxii) of the Order is not applicable.

**For PUNDARIKASHYAM AND ASSOCIATES**

Chartered Accountants

Firm Reg. No: 011330S

B. SURYA PRAKASA RAO

Partner

Membership No: 205125

UDIN: 25205125BMHZOM1557

Place: Hyderabad

Date: 30<sup>th</sup> May, 2025

**ANNEXURE 'B' TO THE INDEPENDENT AUDITORS' REPORT**

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the Internal Financial Controls over Financial Reporting of **M/s. CURA TECHNOLOGIES LIMITED** as of March 31, 2025 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

**Management's Responsibility for Internal Financial Controls**

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of

Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013 to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

### **Meaning of Internal Financial Controls over Financial Reporting**

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external

purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that:

- (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
- (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of Management and directors of the Company; and
- (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper Management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control

over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

**Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For PUNDARIKASHYAM AND ASSOCIATES**

Chartered Accountants

Firm Reg. No: 011330S

B. SURYA PRAKASA RAO

Partner

Membership No: 205125

UDIN: 25205125BMHZOM1557

Place: Hyderabad

Date: 30<sup>th</sup> May, 2025

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

#### **Disclosure of Significant Accounting Policies:**

#### **Note 1: Basis for Preparation of Financial Statements:**

##### **a) Compliance with Indian Accounting Standards (Ind AS)**

The Ind AS financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 notified under section 133 of the Companies Act, 2013.

The Ind AS financial statements have been prepared on the historical cost basis except for certain instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Accordingly, the Company has prepared these Financial Statements which comprise the Balance Sheet as at 31<sup>st</sup> March, 2025 the Statement of Profit and Loss for the year ended 31<sup>st</sup> March, 2025 the Statement of Cash Flows, Statement of Changes in Equity for the year ended 31<sup>st</sup> March, 2025 and accounting policies and other explanatory information (together hereinafter referred to as 'Ind AS Financial Statements' or 'financial statements').

##### **b) Basis of Preparation of financial statements**

The separate financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) under historical cost convention on accrual basis as per the provisions of Companies Act 2013.

- Financial instruments – measured at fair value;
- Assets held for sale—measure daft air value less cost of sale;
- Plan assets under defined benefit plans—measure daft air value
- Employee share-based payments—measure daft air value
- Biological assets—measure daft air value
- In addition, the carrying values of recognized assets and liabilities, designated as hedged items in fair value hedges that would otherwise be carried at cost, are adjusted to record changes in the fair values attributable to the risks that are being hedged in effective hedge relationship.

#### **Current and Non-Current Classification:**

The Company presents assets and liabilities in the balance sheet based on current / non-current classification. An asset is classified as current when it satisfies any of the following criteria:

- It is expected to be realized in, or is intended for sale or consumption in, the Company's normal operating cycle. it is held primarily for the purpose of being traded;
- It is expected to be realized within 12 months after the reporting date; or
- It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.
- All other assets are classified as non-current.
- A liability is classified as current when it satisfies any of the following criteria:
- It is expected to be settled in the Company's normal operating cycle;

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

- It is held primarily for the purpose of being traded
- It is due to be settled within 12 months after the reporting date; or the Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification
- All other liabilities are classified as non-current

**c) Use of estimates and judgment**

The preparation of the financial statements in conformity with Ind AS, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

This note provides an overview of the areas where there is a higher degree of judgment or complexity. Detailed information about each of these estimates and judgments is included in relevant notes together with information about the basis of calculation.

The areas involving critical estimates or judgments are:

S. No	Name of the estimate	Note No	Remarks
1	Fair value of unlisted equity securities	Note 4	unlisted equity shares are held by the company during the current financial year
2	Goodwill impairment	Not applicable	No amount provided during the current financial year
3	Useful life of intangible asset	Not Applicable	No intangible assets held by the company for the current financial year
4	Measurement of contingent liabilities and contingent purchase consideration in a business combination	Not applicable	Contingent transactions are recognized based on happening contingent event. No contingent liabilities for the report
5	Current tax expense and current tax payable	Note No.7	As per the Ind AS.12
6	Deferred tax assets for carried forward tax losses	Note No.7	As per the Ind AS.12
7	Impairment of financial assets	Not Applicable	As per Ind AS 16

- d)** Standards issued but not effective (based on Exposure drafts available as on date)  
The amendments are proposed to be effective for reporting periods beginning on or after 1 April 2020.

**e) Issue of Ind AS117–Insurance Contracts:**

Ind AS 117 supersedes Ind AS 104 Insurance contracts. It establishes the principles for the recognition, measurement, presentation and disclosure of insurance contracts within the scope of the

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

standard. Under the Ind AS 117 model, insurance contract liabilities will be calculated as the present value of future insurance cash flows with a provision for risk.

#### 2. **Significant accounting policies:**

A summary of the significant accounting policies applied in the preparation of the financial statements is as given below. These accounting policies have been applied consistently to all the periods presented in the financial statements.

#### 2.1 **Ind AS 105: Non-Current Assets held for Sale or Discontinued Operations:**

This standard specifies accounting for assets held for sale, and the presentation and disclosure for discontinued operations:

- (a) Assets that meet the criteria to be classified as held for sale to be measured at the lower of carrying amount and fair value less cost to sell, and depreciation on such assets to cease; and
- (b) Assets that meet the criteria to be classified as held for sale to be presented separately in the balance sheet and the results of discontinued operations to be presented separately in the statement of profit and loss.

S. No	Particulars of Disclosures	As at 31 <sup>st</sup> March 2025 (Rs.)	As at 31 <sup>st</sup> March 2024 (Rs.)
1	A Description of Non-Current Asset (Disposal group)	-	-
2	a description of the facts and circumstances of the sale, or leading to the expected disposal, and the expected manner and timing of that disposal	-	-
3	the gain or loss recognized in accordance with paragraphs 21 – 22 and, if not separately presented in the statement of profit and loss, the caption in the statement of profit and loss that includes that gain or loss	-	-

#### 2.2 **Ind AS 106: Exploration for Evolution of Mineral resources:**

This standard specifies the financial reporting for the exploration for evaluation of mineral resources. In particular, this standard requires:

- a. Limited improvements to existing accounting practices for exploration and valuation of expenditures

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

- b. Entities that recognize exploration and evaluation of assets to assess such assets for impairment in accordance with this standard and measure any impairment. Disclosures that identify and explain the amounts in the entity's financial statements arising from the exploration for the evaluation of mineral resources and help users of those financial statements understand the amount, timing and certainty of future cash flows from any exploration and evaluation of assets recognized.

This Ind AS 106 not applicable, the company is in the business of Infrastructure. Hence this Ind AS does not have any financial impact on the financial statements of the company.

#### 2.3 **Ind AS-16: Property, Plant and Equipment:**

Property, Plant and Equipment are stated at cost less accumulated depreciation.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labor, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

Property, plant and equipment which are significant to the total cost of that item of Property Plant and Equipment and having different useful life are accounted for as separately.

Gains or losses arising from derecognition of property, plant and equipment are measured as the difference between the net disposal proceeds and carrying amount of the asset is recognized in the statement of profit or loss when the asset is derecognized.

Depreciation on Property Plant and Equipment is provided on Straight line method. Depreciation is provided based on useful life as prescribed under part C of the schedule II of the Companies act, 2013.

S.no	Asset	Useful life in Years
1	Plant and Machinery	3-60
2	Electrical Installations	2-40
3	Computers	3-10
4	Office Equipment	2-20
5	Furniture & Fixtures	3-15

Depreciation on additions (disposals) is provided on a pro-rata basis i.e. from (upto) the date on which asset is ready for use (disposed of).

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

#### **Impairment**

Property Plant and Equipment are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less cost of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units).

#### **2.4 Impairment Assets (Ind AS 36)**

The Company's non-financial assets, other than deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the statement of profit and loss. Impairment loss recognised in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets of the CGU (or group of CGUs) on a pro rata basis.

The books of accounts of the company doesn't carry any impairment of assets during the reporting period, hence this accounting standard does not have financial impact on the financial statements of the company.

#### **2.5 Intangible assets (Ind AS 38):**

Intangible assets are amortized over the estimated useful lives and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method are reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as change in accounting estimates.

The amortization expense on intangible assets with finite useful lives is recognized in profit or loss.

The books of accounts of the company carry Intangible assets during the reporting period, and its financial impact on the financial statements of the company is properly valued and accounted.

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

#### 2.6 Cash Flow Statement (Ind AS 7):

Cash flows are reported using the indirect method under Ind AS 7, whereby profit/(loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

#### a). Non-cash items: Nil

#### 2.7 Operating Cycle:

The Company has adopted its normal operating cycle as twelve months based on the nature of products and the time between the acquisition of assets for processing and their realization, for the purpose of current / non-current classification of assets and liabilities.

#### 2.8 Capital Work in Progress

The Books of Accounts of Company carry Capital work-in-progress during the reporting period.

#### 2.9 Investments:

**Investments are classified as Non-Current and Current investments.**

Investments, which are readily realisable and are intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as non-current investments.

Current investments are carried at lower of cost and fair value. Non-Current Investments are carried at cost less provision for other than temporary diminution, if any, in value of such investments.

The Books of Accounts of Company have Investments during the reporting period.

#### 2.10 Effects of changes in foreign Rates (Ind AS 21):

Foreign currency transactions are recorded at the exchange rates prevailing on the dates when the relevant transactions took place. Exchange difference arising on settled foreign currency transactions during the year and translation of assets and liabilities at the year-end are recognized in the statement of profit and loss.

In respect of Forward contracts entered into to hedge risks associated with foreign currency fluctuation on its assets and liabilities, the premium or discount at the inception of the contract is amortized as income or expense over the period of contract. Any profit or loss arising on the cancellation or renewal of forward contracts is recognized as income or expense in the period in which such cancellation or renewal is made. The company has not entered any foreign exchange transactions during the reporting period; hence this accounting standard does not have financial impact on the financial statements.

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

#### 2.11 **Borrowing Costs (Ind AS 23):**

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets is substantially ready for the intended use or sale.

Investment income earned on temporary investment of specific borrowings pending their expenditure on qualifying assets is recognized in statement of profit and loss.

Discounts or premiums and expenses on the issue of debt securities are amortized over the term of related securities are included within borrowing costs. Premiums payable on early redemptions of debt securities, in lieu of future costs, are recognized as borrowing costs.

All other borrowing costs are recognized as expenses in the period in which it is incurred.

#### 2.12 **Revenue Recognition (Ind AS 18-Revenues):**

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognized:

- a) Sales Revenue is recognized on dispatch to customers as per the terms of the order. Gross sales are net of returns and applicable trade discounts and excluding GST billed to the customers.
- b) Subsidy from Government is recognized when such subsidy has been earned by the company and it is reasonably certain that the ultimate collection will be made.
- c) Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head “other income” in the statement of profit and loss.
- d) All other incomes are recognized based on the communications held with the parties and based on the certainty of the incomes.

#### 2.13 **Accounting for Government Grants and Disclosure of Government Assistance (Ind AS 20):**

##### **Government grants:**

Government grants are not recognized until there is reasonable assurance that the Company will comply with the conditions attached to them and that the grants will be received.

Government grants are recognized in the Statement of Profit and Loss on a systematic basis over the years in which the Company recognizes as expenses the related costs for which the grants are intended to compensate or when performance obligations are met.

Government grants, whose primary condition is that the Company should purchase, construct or otherwise acquire non-current assets and non-monetary grants are recognized and disclosed as ‘deferred income’ under non-current liability in the Balance Sheet and transferred to the Statement of Profit and Loss on a systematic and rational basis over the useful lives of the related assets.

The benefit of a government loan at a below-market rate of interest and effect of this favorable interest is treated as a government grant. The loan or assistance is initially recognized at fair value and the government grant is measured as the difference between proceeds received and the fair value of the loan based on prevailing market interest rates and recognized to the income statement immediately on

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

fulfillment of the performance obligations. The loan is subsequently measured as per the accounting policy applicable to financial liabilities.

The company has not received any Government Grants during the reporting period; hence this accounting standard does not have financial impact on the financial statements.

#### 2.14 Inventories (Ind AS 2):

Inventories at the year-end are valued as under:

Raw Materials, Packing Material, Components, Consumables and Stores & Spares	At Cost as per First in First Out Method (FIFO).
Work in Progress and Finished goods	At lower of net realizable value and Cost of Materials plus Cost of Conversion and other costs incurred in bringing them to the present location and condition.

- Cost of Material excludes duties and taxes which are subsequently recoverable.
- Stocks at Depots are inclusive of duty, wherever applicable, paid at the time of dispatch from Factories.
- Based on the information provided the difference between physical verification and valuation of the of inventories are charged to the profit and loss account.

#### 2.15 Trade Receivables – Doubtful debts:

Provision is made in the Accounts for Debts/Advances which is in the opinion of Management Are Considered doubtful of Recovery.

#### 2.16 Retirement and other Employee Benefits:

Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than contribution payable to the provident fund. The Company recognizes contribution payable to the provident fund scheme as expenditure, when an employee renders related service.

Gratuity liability is a defined benefit obligation and the cost of providing the benefits under this plan is determined on the basis of actuarial valuation at each year-end. Actuarial valuation is carried out for this plan using the projected unit credit method. Actuarial gains and losses for defined benefits plan is recognized in full in the period in which they occur in the statement of profit and loss.

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

The Company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for based on the actuarial valuation using the projected unit credit method at the year-end. Actuarial gains/losses are immediately taken to the statement of profit and loss and are not deferred. The Company presents the leave as a current liability in the balance sheet, to the extent it does not have an unconditional right to defer its settlement for 12 months after the reporting date.

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

#### 2.17 Ind AS 17- Leases

A Lease is classified as a Finance Lease if it transfers substantially all the risks and rewards incidental to ownership. A lease is classified as an operating lease if it does not transfer substantially all the risks and rewards incidental to ownership.

Finance charges in respect of finance lease obligations are recognized as finance costs in the statement of profit and loss. In respect of operating leases for premises, which are cancellable / renewable by mutual consent on agreed terms, the aggregate lease rents payable is charged as rent in the Statement of Profit and Loss.

#### 2.18 Insurance Claims:

Insurance Claims are accounted for on the basis of claims admitted/expected to be admitted and to the extent that the amount recoverable can be measured reliably and it is reasonable to expect ultimate collection.

#### 2.19 Earnings per Share (Ind AS 33):

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Partly paid equity shares are treated as a fraction of an equity share to the extent that they are entitled to participate in dividends relative to a fully paid equity share during the reporting period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

#### 2.20 Provisions, Contingent Liabilities and Contingent Assets (Ind AS 37):

The Company recognized provisions when there is present obligation as a result of past event and it is probable that there will be an outflow of resources required to settle the obligation in respect of which a reliable estimate can be made. A disclosure for Contingent liabilities is made when there is a possible obligation or present obligations that may, but probably will not, require an outflow of resources. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates. Contingent assets are neither recognized nor disclosed in the financial statements.

##### Contingent Liabilities not provided for and commitments:

(Amount in lakhs)

Nature of Contingent Liability	March 31, 2025	March 31, 2024
i. Unexpired guarantees issued on behalf of the company by Banks for which the Company has provided counter guarantee	Nil	Nil

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

ii. Bills discounted with banks which have not matured	Nil	Nil
iii. Corporate Guarantees issued by Company on behalf of others to Commercial Banks & Financial Institutions	Nil	Nil
iv. Collateral Securities offered to Banks for the limit Sanctioned to others	Nil	Nil
v. Legal Undertakings given to Customs Authorities for clearing the imports	Nil	Nil
vi. Claims against the company not acknowledged as debts		
a. Excise	Nil	Nil
b. Sales Tax	Nil	Nil
c. Service Tax	Nil	Nil
d. Income Tax	Nil	Nil
e. Civil Proceedings	Nil	Nil
f. Company Law Matters	Unascertainable	Unascertainable
g. Criminal Proceedings	Unascertainable	Unascertainable
h. Others	Nil	Nil
vii. Estimated amounts of contracts remaining to be executed on Capital Account and not provided for	Nil	Nil

#### 2.21 Prior Period and Extraordinary and Exceptional Items:

- (i) All Identifiable items of Income and Expenditure pertaining to prior period are accounted through ‘‘Prior Period Items’’.
- (ii) Extraordinary items are income or expenses that arise from events or transactions that are clearly distinct from the ordinary activities of the enterprise and, therefore, are not expected to recur frequently or regularly. The nature and the amount of each extraordinary item be separately disclosed in the statement of profit and loss in a manner that its impact on current profit or loss can be perceived.
- (iii) Exceptional items are generally non-recurring items of income and expenses within profit or loss from ordinary activities, which are of such, nature or incidence.

#### 2.22 Financial Instruments (Ind AS 107 Financial Instruments: (Disclosures)

##### I. Financial assets:

##### A. Initial recognition and measurement

All financial assets and liabilities are initially recognized at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, which are not at fair value through profit or loss, are adjusted to the fair value on initial recognition.

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

#### a) financial assets carried at amortized cost (AC)

A financial asset is measured at amortized cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

#### b) financial assets at fair value through profit or loss (FVTPL)

A Financial asset which is not classified as AC or FVOCI are measured at FVTPL e.g. investments in mutual funds. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss is recognised in profit or loss and presented net in the Statement of Profit and Loss within other gains/(losses) in the period in which it arises.

#### c) financial assets at fair value through other comprehensive income (FVTOCI)

A financial asset is measured at FVTOCI if it is held within a business model whose Objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

### B. Investments in subsidiaries

The Company has accounted for its investments in subsidiaries at cost and not adjusted to fair value at the end of each reporting period. Cost represents amount paid for acquisition of the said investments.

## II. Financial Liabilities

### A. Initial recognition

All financial liabilities are recognized at fair value.

### B. Subsequent measurement

Financial liabilities are carried at amortized cost using the effective interest method. For trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

### 2.23 Operating Segments (Ind AS 108)

Operating segment is a component of an entity:

- a. That engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity).
- b. Whose operating results are regularly reviewed by the entity's chief operating decision maker to make decision about resources to be allocated to the segments and assess its performance, and
- c. For which discrete financial information is available.

The company is in the business Infrastructure. Hence IND AS 108 is not applicable.

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

#### 2.24 Events After the Reporting Period (Ind AS-10)

Events after the reporting period are those events, favorable and unfavorable, that occur between the end of the reporting period and the date on which financial statements are approved by the Board of Directors in case of accompany, and, by the corresponding approving authority in case of any other entity for issue. Two types of events can be identified:

- a. Those that provide evidence of conditions that existed at the end of the reporting period (adjusting events after the reporting period) and
- b. Those that are indicative of conditions that arose after the reporting period (non-adjusting events after the reporting period).

An entity shall adjust the amounts recognized in its financial statements to reflect adjusting events after the reporting period.

#### 2.25 Construction Contracts (Ind AS -11):

Construction contract is a contract specifically negotiated for the construction of an asset or a combination of assets that are closely interrelated or interdependent in terms of their design, technology, and function or their ultimate purpose or use.

The company does not have any construction contracts for the year ended.

#### 2.26 Income Taxes (Ind AS 12)

Tax Expense for the period comprises of current and deferred tax.

- **Current Tax:**

Current Tax on Income is determined and provided on the basis of taxable income computed in accordance with the provisions of the Income Tax Act, 1961.

In the year in which 'Minimum Alternative Tax' (MAT) on book profits is applicable and paid, eligible MAT credit equal to the excess of MAT paid over and above the normally computed tax, is recognized as an asset to be carried forward for set off against regular tax liability when it is probable that future economic benefit will flow to the Company within the MAT credit Entitlement period as specified under the provisions of Income Tax Act, 1961.

- **Deferred Taxes:**

Deferred tax liabilities are recognized for all timing differences. Deferred tax assets are recognized for deductible timing differences only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

At each reporting date, the Company re-assesses unrecognized deferred tax assets. It recognizes unrecognized deferred tax asset to the extent that it has become reasonably certain or virtually

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized.

The carrying amount of deferred tax assets are reviewed at each reporting date. The Company writes-down the carrying amount of deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

#### **2.27 Retirement and other Employee Benefits:**

Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than contribution payable to the provident fund. The Company recognizes contribution payable to the provident fund scheme as expenditure, when an employee renders related service.

Gratuity liability is a defined benefit obligation and the cost of providing the benefits under this plan is determined on the basis of actuarial valuation at each year-end. Actuarial valuation is carried out for this plan using the projected unit credit method. Actuarial gains and losses for defined benefits plan is recognized in full in the period in which they occur in the statement of profit and loss.

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

The Company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for based on the actuarial valuation using the projected unit credit method at the year-end. Actuarial gains/losses are immediately taken to the statement of profit and loss and are not deferred. The Company presents the leave as a current liability in the balance sheet, to the extent it does not have an unconditional right to defer its settlement for 12 months after the reporting date.

#### **2.28 Related Party Disclosures (Ind AS 24):**

Related Party disclosures required as per Accounting Standard (Ind AS-24) on “Related Party disclosures”.

#### **2.29 Consolidated and Separate Financial Statement (Ind AS 27):**

The company has no subsidiary companies for the current reporting period. Hence consolidate and separate financial statement are not applicable.

#### **2.30 Investments in Associates (Ind AS 28):**

The company has not made an investment in its associate company during the reporting period. This accounting standard has financial impact on the financial statements for the current reporting period.

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

#### 2.31 Interest in Joint Ventures (Ind AS 31):

The company has no interest in any Joint ventures. This accounting standard has no financial impact on the financial statements for the current reporting period.

#### 2.32 Earnings Per Share (Ind AS 33):

- a) **Basic Earnings Per Share** for (continued operations) there are no discontinued operations hence, EPS is presented for continued operations only.

##### Basic Earnings Per Share (continued operations)

(Amt. in Lakhs)

Particulars	Year ended March 31, 2025	Year ended March 31, 2024
Nominal Value of Equity Shares (Rupees per Share fully paid-up)	10	10
Profit after Tax (in Rs.) - (A)	(66.29)	(94.07)
Weighted average number of Equity shares outstanding during the year - (B)	28,57,397	78,84,987
Earnings Per Share (in Rs.) – Basic = (A/B)	(2.320)	(4.825)

- b) **Diluted earnings per share** (continued operations) there are no discontinued operations hence, EPS is presented for continued operations only.

##### Diluted Earnings Per Share (Continued operations)

(Amt. in Lakhs.)

Particulars	Year ended March 31, 2025	Year ended March 31, 2024
Nominal Value of Equity Shares (Rupees per Share fully paid-up)	10	10
Profit after Tax (in Rs.) (A)	(66.29)	(94.07)
Number of Equity shares outstanding during the year (B)	28,57,397	78,84,987
Weighted average number of Equity shares outstanding during the year (C)	(2.320)	(4.825)
Dilutive Equity shares (D)	10	10
Earnings Per Share (in Rs.) – Diluted = A/(C+D)	(66.29)	(94.07)

#### 2.33 Derivative instruments and un-hedged foreign currency exposure:

- a) There are no outstanding derivative contracts as at March 31, 2025 and March 31, 2024.  
b) Particulars of Un-hedged foreign currency exposure is: Nil

#### 2.34 Confirmation of Balances

Confirmation letters have been issued by the company to Trade Receivables, Trade Payables, Advances to suppliers and others advances requesting that the confirming party responds to the company only if the

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

confirming party disagrees with the balances provided in the request and however the company has not received any letters on disagreements.

#### 2.35 Net Current Assets (Rs. in Lakhs)

Particulars	31.03.2025	31.03.2024
Cash and cash equivalents	10.19	77.36
Financial Assets	107.07	-
Other current assets	6.62	-
<b>Total current assets</b>	<b>123.88</b>	<b>77.36</b>
Trade Payables	-	-
Other current liabilities	728.65	-
Provisions	-	-
<b>Total Current Liabilities</b>	<b>728.65</b>	<b>0.00</b>
<b>Net current assets</b>	<b>(604.77)</b>	<b>77.36</b>

#### 2.36 Revenue from Operations:

S. No	Particulars	As at 31 <sup>st</sup> March 2025	As at 31 <sup>st</sup> March 2024
1	Revenue from Sale of Service	-	-
2	Other Operating Revenues	-	-

#### 2.37 Revenue Reconciliation:

S. No	Particulars	As at 31 <sup>st</sup> March 2025	As at 31 <sup>st</sup> March 2024
1	Sale of Products	-	-
2	Domestic	-	-
3	Exports	-	-
4	Gross Revenue	-	-
5	Less: Discount	-	-
6	Less: Returns	-	-
7	Less: price Concession	-	-
8	Less Incentives and Performance bonus	-	-
9	Less: Goods and service Tax	-	-
10	Net Revenues recognized from contracts with customers	-	-

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

#### 2.38 Details of Loans given, Investments made and Guarantee given covered Under Section 186(4) of the Companies Act, 2013.

The company has not extended any Corporate Guarantees in respect of loans availed by any company/firm as at March 31, 2025.

#### 2.39 Dues to Micro Small and Medium Enterprises:

Disclosure required as per section 22 of the Micro, Small and Medium Enterprise Development Act, 2006 (MSMED Act.) as at 31.03.2023.

S. No.	Description	March 31, 2025	March 31, 2024
1	Principal amount due to suppliers under MSMED	NIL	NIL
2	Interest accrued and due to suppliers covered under MSMED on the above amount, unpaid	NIL	NIL
3	Payment made to suppliers (with Interest) beyond the appointed day during the year.	NIL	NIL
4	Payment made to suppliers (other than interest) beyond the appointed day during the previous year	NIL	NIL
5	Interest paid to suppliers covered under MSMED	NIL	NIL
6	Interest due & Payable to suppliers covered under MSMED Act., towards payments already made.	NIL	NIL

The information has been given in respect of such vendors to the extent they could be identified as micro and small enterprises on the basis of information available with company.

#### 2.40 Financial Risk Management

In course of its business, the company is exposed to certain financial risk such as market risk (Including currency risk and other price risks), credit risk and liquidity risk that could have significant influence on the company's business and operational/financial performance. The Board of directors reviews and approves risk management framework and policies for managing these risks and monitor suitable mitigating actions taken by the management to minimize potential adverse effects and achieve greater predictability to earnings.

#### 2.41 Credit Risk

Credit risk refers to the risk that counterparty will default on its contractual obligations resulting in financial loss to the company. The company has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, a means of mitigating the risk of financial loss from defaults.

The company makes an allowance for doubtful debts/advances using expected credit loss model.

**CURA TECHNOLOGIES LIMITED**

**Significant Accounting Policies and notes to Accounts forming of Financial Statements  
as at 31<sup>st</sup> March, 2025**

**2.42 Liquidity risk**

Liquidity risk refers to the risk that the company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as pre requirements. The Company's exposure to liquidity risk is minimal as the promoters of the company is infusing the funds based on the requirements.

**2.43** Rupees have been rounded off to nearest lakhs.

**For Pundarikashyam & Associates**

Chartered Accountants  
Firm Regn. No.011330S

**For and on behalf of  
CURA TECHNOLOGIES LIMITED**

B. Surya Prakasa Rao  
Partner  
Membership No. 205125  
Place: Hyderabad

Sangareddypeta Saikiran  
Whole-time Director and CFO  
DIN: 09741325

Sanjana Lagumavarapu  
Managing Director  
DIN: 09440632

Date: 30-05-2025  
UDIN: 25205125BMHZOM1557

Sharvari Shinde  
Company Secretary and Compliance Officer

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

#### Note 13: Other Statutory Information

- i. The title deeds of immovable properties held in the name of Company, are acquired as a part of amalgamation of M/s Catalogue Solutions Private Limited.
- ii. The Company has not revalued its property, plant & equipment during the year.
- iii. There are no Loans or Advances granted to promoters, Directors, KMPs and the related parties (as defined under Companies Act, 2013,) either severally or jointly with any other person.
- iv. Ageing schedule of Capital Work-in-Progress is separately annexed.
- v. There are no intangible assets under development at the year-end.
- vi. The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- vii. The Company has no borrowings from banks or financial institutions on the basis of security of current assets.
- viii. The Company has not been declared as a willful defaulter by any lender who has powers to declare a company as a willful defaulter at any time during the financial year or after the end of reporting period but before the date when the financial statements are approved.
- ix. Disclosure of Transactions with struck off Companies - The Company does not have any transactions with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the financial year.
- x. The Company do not have any charges or satisfaction which are yet to be registered with ROC beyond the statutory period.
- xi. The Company has not invested in any other Companies, hence the compliance with regards to the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017 is not applicable.
- xii. The ratio analysis of the company is separately annexed.
- xiii. The disclosure regarding Scheme of Arrangements being approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013 is not applicable.
- xiv. The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
  - (a) directly or indirectly lends or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries), or
  - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- xv. The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

## CURA TECHNOLOGIES LIMITED

### Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025

- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
- xvi. The provisions contained in Section 135 of the Act relating to CSR Activities are not applicable to the company for the year under review.
- xvii. The Company have not traded or invested in Crypto currency or Virtual Currency during the financial year.
- xviii. The Company does not have transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- xix. The company has no borrowings from Banks and Financial institutions So, the question of usage of the borrowings from banks and financial institutions for the specific purpose for which it was taken at the balance sheet date does not arise.

#### Note 14:

- Based on our examination which included test checks, the Company has used accounting software for maintaining its books of accounts for the year ended 31st March,2025 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software except that, audit trail feature is not enabled for direct changes to database when using certain access rights. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with, in respect of accounting software where the audit trail has been enabled.
- As proviso to Rule 3(1) of the Companies (Accounts) Rules,2014 is applicable from 1st April, 2023, reporting under Rule 11 (g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended 31st March, 2025.

#### Note 15:

##### Amalgamation of Catalog IT Solutions Private Limited

- On 13th February, 2025, the Company completed the merger of Catalog IT Solutions Private Limited via an all-equity merger under which 10 shares of Cura Technologies Limited (the Company) were allotted for every share of Catalog IT Solutions Private. With this merger the Company acquired the business of Catalog IT Solutions Private Limited.
- The scheme of merger(“scheme”) submitted by the Company was approved by Hon’ble National Company Law Tribunal by its order dated 14th September, 2023 (Hyderabad bench). The Board of

## **CURA TECHNOLOGIES LIMITED**

### **Significant Accounting Policies and notes to Accounts forming of Financial Statements as at 31<sup>st</sup> March, 2025**

Directors approved the scheme between the Company and Catalog IT Solutions Private, on 13<sup>th</sup> February, 2025.

- The merger aligned with the company's strategy to build a sustainable and profitable Information Technology (IT) business by leveraging the growing demand for digital transformation and enterprise solutions. The merger has been accounted for using the acquisition accounting method under Ind AS 103 – Business Combinations.

#### **For Pundarikashyam & Associates**

Chartered Accountants  
Firm Regn. No.011330S

#### **For and on behalf of CURA TECHNOLOGIES LIMITED**

B. Surya Prakasa Rao  
Partner  
Membership No. 205125  
Place: Hyderabad

Sangareddypeta Saikiran  
Whole-time Director and CFO  
DIN: 09741325

Sanjana Lagumavarapu  
Managing Director  
DIN: 09440632

Date: 30-05-2025  
UDIN: 25205125BMHZOM1557

Sharvari Shinde  
Company Secretary and Compliance Officer

**BALANCE SHEET as at March 31, 2025**

(Amount in lakhs)

Particulars	Note No.	As at 31st March, 2025	As at 31st March, 2024
<b>A ASSETS</b>			
<b>1 Non-Current Assets</b>			
(a) Property, Plant and Equipment	3	177.47	-
(b) Capital Work in Progress		-	-
(c) Investment Property			
(d) Goodwill	3	1,585.27	
(e) Other Intangible Assets	3	0.13	-
(f) Intangible assets under development			
(g) Biological Assets other than bearer plants			
(h) <b>Financial Assets</b>			-
(i) Investments		-	-
(i) Long-term Loans & Advances		-	-
(e) Other non-current assets			-
(f) Deferred Tax Asset			-
<b>Total Non-Current Assets</b>		<b>1,762.87</b>	<b>-</b>
<b>2 Current Assets</b>			
(a) <b>Financial Assets</b>			
(i) Investments			-
(ii) Trade Receivables		-	-
(iii) Cash and Cash Equivalents	4	10.19	77.36
(iv) Bank balances other than (iii) above			
(v) Loans & Advances		107.07	-
(vi) Other financial assets		-	-
(b) Current Tax Assets (Net)		-	-
(c) Other current assets	5	6.62	-
<b>Total Current Assets</b>		<b>123.88</b>	<b>77.36</b>
<b>Total Assets</b>		<b>1,886.76</b>	<b>77.36</b>
<b>II EQUITY AND LIABILITIES</b>			
<b>1 Equity</b>			
(a) Equity share capital	6	915.00	195.00
(b) Share Application Money Pending allotment		-	19.23
(c) Other equity	7	(203.16)	(136.87)
<b>Total Equity</b>		<b>711.84</b>	<b>77.36</b>
<b>2 Non-Current Liabilities</b>			
(a) <b>Financial Liabilities</b>			
(i) Borrowings	8	446.27	
(ii) Other financial liabilities		-	-
(b) Provisions		-	-
(c) Deferred tax liabilities (Net)		-	-
(d) Other non-current liabilities			
<b>Total Non-Current Liabilities</b>		<b>446.27</b>	<b>-</b>
<b>3 Current Liabilities</b>			
(a) <b>Financial Liabilities</b>			
(i) Borrowings		-	-
(ii) Trade Payables		-	-
(iii) Other Financial Liabilities			-
(b) Other current liabilities	9	728.65	-
(c) Provisions			-
(d) Current Tax Liabilities (Net)		-	-
<b>Total Current Liabilities</b>		<b>728.65</b>	<b>-</b>
<b>Total Equity and Liabilities</b>		<b>1,886.75</b>	<b>77.36</b>

Significant accounting policies and notes to the Ind AS financial statements

1-18

The explanatory notes referred to above form an integral part of the Financial statements

As per our Report on the even date attached

**For and on behalf of the Board of Directors  
For Cura Technologies Limited**

**For Pundarikashyam & Associates**

Chartered Accountants

Firm Regn. No.0113305

S. Sai Kiran

Whole Time Director & CFO

DIN: 09741325

B. Surya Prakasa Rao

Partner

Membership No. 205125

Place: Hyderabad

Date: 30-05-2025

UDIN: 25205125BMHZOM1557

Sanjana Lagumavarapu

Managing Director

DIN: 09440632

Sharvari Shinde

Company Secretary and Compliance Officer

## CURA TECHNOLOGIES LIMITED

Unit No. 604 B, Jain Saduguru Capital Park, Beside Image Gardens, Madhapur,  
Hyderabad, Shaikpet, Telangana, India, 500081  
CIN: L84120TG1991PLC013479  
Email ID: cs@curatechnologies.in  
Website: curatechnologies.in

### STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2025

(Amount in Lakhs)

Particulars	Note No.	For the Year Ended 31.03.2025	For the Year Ended 31.03.2024
I Revenue from operations		-	-
Other income		-	-
<b>Total income (I + II)</b>		<b>-</b>	<b>-</b>
II <b>Expenses:</b>			
Cost of materials consumed		-	-
Purchases of stock-in-trade			
Changes in inventories of finished goods and work-in-progress		-	-
Employee benefits expenses	10	4.83	-
Finance costs	11	0.01	-
Depreciation and amortisation expenses	3	0.06	-
Other expenses	12	61.40	94.08
<b>Total expenses</b>		<b>66.29</b>	<b>94.08</b>
III <b>Profit/(loss) before exceptional item and tax (III-IV)</b>		(66.29)	(94.08)
IV Extraordinary Items		-	-
V <b>Profit/(loss) before tax (V-VI)</b>		<b>(66.29)</b>	<b>(94.08)</b>
VI Tax expenses:			
Current tax		-	-
MAT Credit Entitlement		-	-
VII <b>Profit/ (loss) for the period from continuing operations (V - VI)</b>		(66.29)	(94.08)
VIII Profit/ (loss) from discontinued operations		-	-
IX Tax expense of discontinued operations		-	-
X <b>Profit/ (loss) from discontinued operations (after tax) (VIII - IX)</b>		-	-
XI <b>Profit/ (loss) for the period (VII + X)</b>		(66.29)	(94.08)
XII Other Comprehensive income/(loss)		-	-
XIII <b>Total Comprehensive income/(loss) for the year (XI + XII)</b>		<b>(66.29)</b>	<b>(94.08)</b>
XIV <b>Earnings per equity share (of Rs. 1/- each)</b>			
Basic		<b>(2.320)</b>	<b>(4.825)</b>
Diluted		<b>(2.320)</b>	<b>(4.825)</b>

Significant accounting policies and notes to the Ind AS financial statements

1-18

The explanatory notes referred to above form an integral part of the Financial statements

As per our Report on the even date attached

For and on behalf of the Board of Directors  
For Cura Technologies Limited

For Pundarikashyam & Associates  
Chartered Accountants  
Firm Regn. No.0113305

S. Sai Kiran  
Whole Time Director & CFO  
DIN: 09741325

B. Surya Prakasa Rao  
Partner  
Membership No. 205125  
Place: Hyderabad  
Date: 30-05-2025  
UDIN: 25205125BMHZOM1557

Sanjana Lagumavarapu  
Managing Director  
DIN: 09440632

Sharvari Shinde  
Company Secretary and Compliance Officer

**CURA TECHNOLOGIES LIMITED**

Unit No. 604 B, Jain Saduguru Capital Park, Beside Image Gardens, Madhapur,  
Hyderabad, Shaikpet, Telangana, India, 500081

CIN No.- L84120TG1991PLC013479

**STATEMENT OF CASH FLOW STATEMENT FOR THE YEAR 2024-25**

(Amount in Lakhs.)

1	CASH FLOW FROM OPERATING ACTIVITIES	For the Year Ended 31.03.2025	For the Year Ended 31.03.2024
	Net Profit before taxation	(66.29)	(94.08)
	<u>Adjustment for:</u>		
	Depreciation	0.06	-
	Interest received	-	-
	Transfer to Capital Reserve	-	-
	<b>Operating Profit before Working Capital Changes</b>	<b>(66.23)</b>	<b>(94.08)</b>
	Increase/Decrease in Trade and Other Current Assets	(6.62)	-
	(Decrease) / Increase in Long Term Liabilities	-	-
	Increase/Decrease in Trade Receivable	-	-
	Increase/Decrease in Trade Payables	-	-
	Increase/Decrease in loans & Advances	(107.07)	-
	Increase/Decrease in Other Current Liabilities	728.65	(5.39)
	<b>Cash generated from Operations</b>	<b>548.72</b>	<b>(99.47)</b>
	Income Tax	-	-
	<b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>	<b>548.72</b>	<b>(99.47)</b>
2	<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
	Interest received	-	-
	Sale of Investment	-	-
	Purchase of Property, Plant & Equipment & goodwill	(1,762.92)	-
	<b>NET CASH FLOW FROM INVESTING ACTIVITIES</b>	<b>(1,762.92)</b>	<b>-</b>
3	<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
	Increase/Decrease in Financial Assets	-	-
	Increase/(Decrease) in share capital	720.00	156.67
	Share Application money	(19.23)	0.53
	Unsecured Loan Taken	446.27	-
	<b>NET CASH FLOW FROM FINANCING ACTIVITIES</b>	<b>1,147.04</b>	<b>157.20</b>
	<b>NET INCREASE IN CASH AND CASH EQUIVALENTS</b>	<b>(67.17)</b>	<b>57.73</b>
	<b>Cash and Cash Equivalents at the beginning of the period</b>	<b>77.36</b>	<b>19.64</b>
	<b>Cash and Cash Equivalents at the end of the period</b>	<b>10.19</b>	<b>77.37</b>

Notes:

- The above cash flow statement has been prepared under the "Indirect Method" as set out in the IND AS 7 on Statement of Cash Flow notified under Companies (Accounts) Rules, 2015.
- Figures in brackets represents Cash outflows
- Cash & Cash equivalents represents Cash & Bank Balances only

**As per our Report on the even date attached**

**For Pundarikashyam & Associates**

Chartered Accountants  
Firm Regn. No.0113305

**B. Surya Prakasa Rao**

Partner  
Membership No. 205125  
Place: Hyderabad  
Date: 30-05-2025  
UDIN: 25205125BMHZOM1557

For and on behalf of the Board of Directors  
For Cura Technologies Limited

S. Sai Kiran  
Whole Time Director & CFO  
DIN: 09741325

Sanjana Lagumavarapu  
Managing Director  
DIN: 09440632

Sharvari Shinde  
Company Secretary and Compliance Officer

**CURA TECHNOLOGIES LIMITED**

Notes annexed to and forming part of the Provisional Balance Sheet as at 31st March, 2025

*(All amounts are stated in lakhs unless otherwise stated)***Note No. 3: Property, Plant & Equipment and Intangible Assets**

ASSET	Gross Block				Depreciation				Net Block	
	As at 31st March 2024	Additions during the Year	Deletions during the Year	As at 31st March 2025	Rate of Dep.	As at 31st March 2024	For the period	As at 31st March 2025	As at 31st March 2025	As at 31st March 2024
<b>A. Property, Plant &amp; Equipment</b>										
Land										
Building		176.91		176.91	-		-	-	176.91	
Computers	-	0.60		0.60	31.67%	-	0.03	0.03	0.57	-
Office Equipment	-			-			-	-	-	-
Library	-			-			-	-	-	-
Vehicles	-			-			-	-	-	-
<b>B. Intangible Assets</b>										
Software	-	0.15		0.15	25.00%	-	0.02	0.03	0.13	-
Goodwill		1,585.27		1,585.27	0.00%		-	-	1,585.27	-
<b>C. Capital Work in Progress</b>										
Capital Work in Progress	-	-	-	-			-	-	-	-
<b>Grand Total</b>	-	<b>1,762.92</b>	-	<b>1,762.92</b>		-	<b>0.05</b>	<b>0.06</b>	<b>1,762.87</b>	-

**CURA TECHNOLOGIES LIMITED**

**CIN NO: L84120TG1991PLC013479**

**Notes annexed to and forming part of the Financial Statements for the year ended 31st March, 2025**

**Note 4: Cash and cash equivalents**

**(Amount in Lakhs)**

S. No	Particulars	As at March 31, 2025	As at March 31, 2024
	<b>Bank and Cash Balances</b>		-
	<b><u>On Current Accounts:</u></b>		-
1	Balances with Scheduled Banks	8.80	77.36
2	Fixed Deposits	-	-
3	Cheques/dafts on hand	-	-
4	Cash on hand	1.39	-
	<b>Total</b>	<b>10.19</b>	<b>77.36</b>

**Note 5: Other Current Assets**

S. No	Particulars	As at March 31, 2025	As at March 31, 2024
1	(a) Security deposits	-	-
	(b) Advances to employees	-	-
	(c) Other Advances	-	-
	(d) TDS Receivable	0.16	-
		-	-
2	(a) VAT/GST Receivable	-	-
	(b) GST recivables	6.47	-
	<b>Total</b>	<b>6.62</b>	-

**Note 8: Borrowings**

S. No	Particulars	As at March 31, 2025	As at March 31, 2024
1	<b><u>TERM LOANS</u></b>		
	From Banks	427.04	-
	Less. Current maturities	-	-
		427.04	-
2	From others	-	-
	Loans from related parties	-	-
	Loans from Others	19.23	19.23
		19.23	19.23
	<b>Total</b>	<b>446.27</b>	<b>19.23</b>

**Note 9: Other Current Liabilities**

S. No	Particulars	As at March 31, 2025	As at March 31, 2024
	Audit fees payable	5.81	-
	Other Current Liabilities	0.47	-
	Other Payables	722.37	-
	<b>Total</b>	<b>728.65</b>	-

**CURA TECHNOLOGIES LIMITED**

**CIN NO: L84120TG1991PLC013479**

**Notes annexed to and forming part of the Financial Statements for the year ended 31st March, 2025**

**Note 10: Employee Benefit Expenses**

<b>S. No</b>	<b>Particulars</b>	<b>As at March 31, 2025</b>	<b>As at March 31, 2024</b>
	Salaries, Wages, Bonus etc.	4.83	-
	Contribution to P.F, E.S.I and Other Statutory Funds	-	-
	Staff welfare expenses	-	-
	<b>Total</b>	<b>4.83</b>	<b>-</b>

**Note 11: Finance Cost**

<b>S. No</b>	<b>Particulars</b>	<b>As at March 31, 2025</b>	<b>As at March 31, 2024</b>
	<b>Interest and finance charges on financial liabilities carried at amortised cost</b>		-
	a). Interest on Bank Borrowings	-	-
	b). Interest on Bill Discounting	-	-
	c). Other Interest Expenses(Bank Charges)	0.01	-
	Less: Amount Capitalised	-	-
	<b>Total</b>	<b>0.01</b>	<b>-</b>

**Note 12: Other Expenses**

<b>S. No</b>	<b>Particulars</b>	<b>As at March 31, 2025</b>	<b>As at March 31, 2024</b>
	<b>Administration Expenses</b>		-
	Resolution Expenses	-	40.82
	CIRP Expenditure	-	53.25
		-	94.07
	Audit Fee	5.00	-
	Professional & Consultancy Fees	13.19	-
	Secretarial Audit Fee	0.10	-
	Physical Demat and Maintenance Charges	1.97	-
	Other Expenses	41.15	-
	<b>Total</b>	<b>61.40</b>	<b>94.07</b>

**CURA TECHNOLOGIES LIMITED**

Notes annexed to and forming part of the Financial Statements for the year ended 31st March, 2024

**Note 6: Equity Share Capital**

**a. Equity share capital**

(Amount in Lakhs)

S. No	Particulars	As at March 31, 2025		As at March 31, 2024	
		No. of Shares	Amount (in Rs.)	No. of Shares	Amount (in Rs.)
	<b>Authorised Capital</b>	-	-	-	-
	Equity shares of Rs. 10/- each	1,00,00,000.00	1,000.00	10.00	100.00
	<b>Issued</b>	-	-	-	-
	Equity shares of Rs. 10/- each	91,50,000.00	915.00	19,50,000.00	195.00
	<b>Subscribed and Paid-up</b>	-	-	-	-
	Equity shares of Rs. 10 each fully paid-up	91,50,000.00	915.00	19,50,000.00	195.00
	<b>Total</b>	<b>91,50,000.00</b>	<b>915.00</b>	<b>19,50,000.00</b>	<b>195.00</b>

**b. Reconciliation of the number of equity shares outstanding and the amount of share capital**

S. No	Particulars	As at March 31, 2025		As at March 31, 2024	
		No. of Shares	Amount (in Rs.)	No. of Shares	Amount (in Rs.)
	<b>Equity Shares</b>				
	<b>Issued and Subscribed:</b>				
	Shares outstanding at the beginning of the year	19,50,000.00	195.00	95,55,000.00	955.50
	Add: Issued During the year for cash	72,00,000.00	720.00	16,09,702.00	160.97
	Add: Shares issued at ESOP trust				-
	Less: Resolution Plan Adjustment A/c			92,14,702.00	921.47
	<b>Shares outstanding at the end of the year</b>	<b>91,50,000.00</b>	<b>915.00</b>	<b>19,50,000.00</b>	<b>195.00</b>

**c. Terms / rights attached to equity Shares**

The company has one class of equity shares having a par value of Rs.10 per share. Each shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion to their shareholdings.

- d.** Shares reserved for issue underwriter options NIL
- e.** Detail of Rights Issues NIL
- f.** Details of shares held by Holding/Ultimatley Holding Company NIL
- g.** Details of shares issued for consideration other than cash NIL
- h. Shares in the company held by each shareholder holding more than 5 percent**

S. No	Name of the Shareholder	As at March 31, 2025		As at March 31, 2024	
		No. of Shares held	% of Holding	No. of Shares held	% of Holding
	Promoter & Promoter Group	74,44,702	81.36%	2,44,702	12.55%
	Public	17,05,298	18.64%	17,05,298	87.45%

**Note7: Other Equity**

S. No	Particulars	As at March 31, 2025	As at March 31, 2024
	<b>Securities Premium:</b>		
	Securities Premium		
	<b>Investment Allowance Reserve</b>		
	As per last balance sheet		
	<b>Subsidy</b>		
	As per last balance sheet		
	<b>Resolution Plan Adjustment A/c</b>		
	As per last balance sheet	(42.80)	(42.80)
	<b>Retained earnings</b>		
	<b>Surplus/(deficit) in the statement of profit and loss</b>		
	Balance at the beginning of the year	(94.07)	(7,092.82)
	Add: Change to Profit/ (Loss) for the years	(66.29)	(94.07)
	Add: Towards Resolution Plan adjustment	-	7,092.82
	<b>Balance at the end of the year</b>	<b>(160.36)</b>	<b>(94.07)</b>
	<b>Total other Equity</b>	<b>(203.16)</b>	<b>(136.87)</b>

**Note No. 16 : Trade Receivables Ageing****Trade Receivables ageing schedule as at 31st March, 2025**

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	-	-	-	-	-	-
(ii) Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables - considered good	-	-	-	-	-	-
(iv) Disputed trade receivables - considered doubtful	-	-	-	-	-	-
<b>Total</b>	-	-	-	-	-	-

**Trade Receivables ageing schedule as at 31st March, 2024**

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	-	-	-	-	-	-
(ii) Undisputed Trade receivables - considered doubtful	-	-	-	-	-	-
(iii) Disputed trade receivables - considered good	-	-	-	-	-	-
(iv) Disputed trade receivables - considered doubtful	-	-	-	-	-	-
<b>Total</b>	-	-	-	-	-	-

**Note No.17 : Trade Payables Ageing****Trade Payables ageing schedule as at 31st March, 2025**

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	-	-	-	-
(ii) Others	-	-	-	-	-
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
<b>Total</b>	-	-	-	-	-

**Trade Payables ageing schedule as at 31st March, 2024**

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	-	-	-	-
(ii) Others	-	-	-	-	-
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
<b>Total</b>	-	-	-	-	-

**For Pundarikashyam and Associates**

Chartered Accountants

FRN: 011330S

**B. Surya Prakasa Rao**

(Partner)

Membership No: 205125

Place: Hyderabad

Date: 30-05-2025

UDIN: 25205125BMHZOM1557

**For Cura Technologies Limited**

S. Sai Kiran

Whole Time Director &amp; CFO

DIN: 09741325

Sanjana Lagumavarapu

Managing Director

DIN: 09440632

Sharvari Shinde

Company Secretary and Compliance Officer